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The transthyretin-associated amyloidoses are a group of protein-folding 
disorders caused by deposition of the liver-secreted plasma protein 
transthyretin (TTR) in various tissues of the body. The sporadic form of 
the disease is caused by deposition of wild-type TTR whereas the 
inherited form is caused by deposition of mutated TTR; there are over 
100 known amyloidogenic mutations of the TTR gene. The 
transcriptional regulation of the mouse transthyretin gene has been well 
studied. Organ-specific modulation of TTR mRNA is achieved by 
coordinated binding of hepatocyte-specific and ubiquitously expressed 
transcription factors to regulatory regions in the proximal promoter and 
vii 
upstream enhancer region. The hypothesis of this dissertation is that 
non-coding genetic sequence variations in the promoter of the 
transthyretin gene situated upstream of the regulatory regions, alter its 
transcriptional regulation, contributing to the onset and expression of 
transthyretin-associated amyloidosis. Previously, we identified a 
significant association of a non-coding polymorphism of the TTR 
promoter, rs3764479, with age of onset and survival in patients with 
ATTRwt amyloid disease. In this dissertation, electrophoretic mobility 
shift assays (EMSA) were used to investigate transcription factor binding 
of HepG2 nuclear proteins to short DNA probes with and without 
rs3764479. These mobility shift studies revealed that HepG2 nuclear 
extract proteins showed higher affinity to the wild-type TTR sequence 
than to one containing the rs3764479 SNP. Competition EMSAs 
suggested SNP-related changes in the binding of transcription factors 
hepatocyte nuclear factor-1 (HNF1) and hepatocyte nuclear factor-3b 
may alter TTR gene transcription. To investigate transthyretin gene 
regulation in V122I ATTR amyloid, the most prevalent TTR gene variant 
in the United States, the proximal promoter region from patients with 
V122I ATTR amyloidosis was sequenced and analyzed. In total, 8 SNPs 
were identified; one (rs955705399) was significantly associated with 
disease between the two V122I genotype-positive cohorts studied with 
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and without cardiomyopathy. It is postulated that the presence of SNPs 
could influence gene expression and ultimately disease pathogenesis. In 
summary, these studies suggest that presence of disease-associated 
non-coding genetic variations modify transthyretin gene expression by 
disrupting transcription factor binding and may, in part, explain the 
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CHAPTER 1. INTRODUCTION 
 
1.1 Amyloid and Amyloidosis 
 Amyloidosis refers to a group of heterogeneous protein misfolding 
disorders that occur when a specific protein misfolds into fibrils, deposits 
in tissues, inducing tissue damage and organ dysfunction. To date, over 
30 proteins are known to be “amyloidogenic” in humans (Sipe et al., 
2016) with the intrinsic ability to misfold, aggregate and form the 
distinctive congophilic fibrils comprising amyloid deposits. A wide range 
of clinical presentations result, depending on the property of the 
amyloidogenic protein and the affected tissue. Localized amyloidosis 
occurs when the misfolded protein is produced and deposited in a single 
target tissue or organ as seen in Alzheimer’s disease (Invernizzi, 
Papaleo, Sabate, & Ventura, 2012; Stefani & Dobson, 2003). Systemic 
amyloidoses, in contrast, are characterized by the extracellular 
deposition of an amyloidogenic protein in multiple tissues in the body 
such as the peripheral and autonomic nervous systems, the heart, and 
other visceral organs (Falk & Skinner, 2000; Kisilevsky, 1991; Merlini & 
Westermark, 2004; Wechalekar, Gillmore, & Hawkins, 2016). The 
deposits found in multiple organs throughout the body are derived from 
circulating plasma protein precursors (Sipe, 1992). Both the total organ 
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burden of extracellular amyloid deposits and cellular toxicity of pre-
fibrillar oligomers contribute to the eventual organ dysfunction (Hou, 
Aguilar, & Small, 2007; Merlini & Westermark, 2004; Reixach, 
Deechongkit, Jiang, Kelly, & Buxbaum, 2004; Sousa, M. M., Cardoso, 
Fernandes, Guimarães, & Saraiva, 2001; Stefani & Dobson, 2003). 
Intracellular signaling and subsequent cytotoxic effects can result from 
the heat shock response or the unfolded protein response (UPR) 
pathways (Stefani & Dobson, 2003).  
 
1.2 Transthyretin 
Deposition of the liver-secreted plasma protein transthyretin 
(TTR), also known as prealbumin, leads to systemic transthyretin-
associated amyloidoses, or ATTR amyloidosis (Felding & Fex, 1982; 
Mita, S., Maeda, Shimada, & Araki, 1986). Transthyretin is a 
thermodynamically stable, 55 kD, circulating homotetramer that is 
primarily made and secreted by the liver (Felding & Fex, 1982; 
Jacobsson, 1989; Mita, S. et al., 1986). Its main functions are to directly 
bind and transport thyroxine (T4) and, indirectly, vitamin A by 
complexing with retinol-binding protein 4 (RBP4) (Bartalena & Robbins, 
1993; Rostom et al., 1998). Minor sites of TTR production include the 
choroid plexus (Dickson, Aldred, Marley, Bannister, & Schreiber, 1986; 
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Herbert et al., 1986), where TTR is thought to have a protective role 
against the development of neurodegenerative disease such as 
Alzheimer’s disease (Buxbaum, J. N. et al., 2008; Li & Buxbaum, 2011; 
Li, Masliah, Reixach, & Buxbaum, 2011), and the retinal epithelium 
(Cavallaro, Martone, Dwork, Schon, & Herbert, 1990). Normal levels of 
transthyretin range from 18 – 45 mg/dL in the serum (Ritchie & 
Navolotskaia, 1996) whereas its concentration in the cerebral spinal 
fluid (CSF) ranges from 10 – 40 µg/mL (Weisner & Roethig, 1983).  
Circulating TTR tetramer consists of four identical subunits that 
are 127 amino acids long (Kanda, Goodman, Canfield, & Morgan, 1974) 
(Figure 1.1). Each subunit is composed of 8 beta sheets (denoted A 
through H), a small number of alpha helices, and unstructured N- and 
C-termini (Blake et al., 1971; Blake, Geisow, Swan, Rerat, & Rerat, 
1974; Blake, Geisow, Oatley, Rérat, & Rérat, 1978; Hamilton et al., 
1993). The dimer-dimer interface of the tetrameric protein creates two 
hydrophobic binding sites for thyroxine, although limited hormone 
transport occurs through this mechanism (Blake et al., 1971; Foss, 
Wiseman, & Kelly, 2005; Raghu & Sivakumar, 2004). In contrast, the 
binding sites for the RBP4 molecules are on the surface of the globular 
homotetramer (Raghu & Sivakumar, 2004) and serve an important role 




Figure 1.1. A ribbon diagram depicting X-ray crystallographic 
appearance of the human transthyretin (TTR) protein 
complexed with two thyroxine molecules. The circulating form 
of the protein is composed of four identical monomers. Each 
monomer is composed of 127 amino acids. The dimer-dimer interface 
has two thyroxine (T4) binding sites (arrows). Thyroxine molecules 
can be seen complexed to the transthyretin protein at the two binding 
pockets. Source: https://www.rcsb.org/structure/2ROX  
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TTR amyloidogenesis (Figure 1.2) requires dissociation of the 
tetramers and release of monomers (Branch, Robbins, & Edelhoch, 
1972; Nilsson, Rask, & Peterson, 1975) - a thermodynamically 
unfavorable process reflected by the tetramer’s high resistance to 
thermal, acid, and urea denaturation (Hammarström, Jiang, Hurshman, 
Powers, & Kelly, 2002; Hurshman Babbes, Powers, & Kelly, 2008; 
McCutchen, Colon, & Kelly, 1993; McCutchen, Lai, Miroy, Kelly, & Colón, 
1995). The dissociation of the tetramer has been shown to be the rate-
limiting step of amyloidogenesis in vitro (Jiang et al., 2001; Jiang, 
Buxbaum, & Kelly, 2001a; Lai, Colón, & Kelly, 1996). Once dissociated, 
the monomers partially unfold, exposing hydrophobic amino acid 
residues that promote aggregation of misfolded monomers, eventually 
forming large fibrils with cross-β sheet amyloid structures (Chiti, 
Stefani, Taddei, Ramponi, & Dobson, 2003; DuBay et al., 2004; 

















Figure 1.2. The amyloid cascade for the TTR protein. The native 
TTR tetramer is a thermodynamically stable conformation, making 
dissociation to monomers the rate limiting step. Once dissociated, 
monomeric TTR partially unfolds and aggregates. Protofibrils or 
protofilaments form and eventually fibrils deposit as amyloid in target 
tissue causing organ dysfunction. 
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1.3 Transthyretin-associated amyloidosis 
Extracellular deposition of mutated or variant TTR (TTRv) leads to 
hereditary transthyretin-related amyloidosis (ATTRv amyloidosis) while 
deposition of wild-type TTR leads to non-hereditary wild-type 
transthyretin-related amyloidosis (ATTRwt amyloidosis) (Cornwell, 
Johnson, & Westermark, 1995; Gertz et al., 2015; Gertz, Dispenzieri, & 
Sher, 2015; Skinner & Cohen, 1981). There are over 140 known variants 
in the highly polymorphic TTR gene of which 130 are associated with 
ATTRv amyloidosis (Rowczenio et al., 2014). The vast majority of these 
variants are single nucleotide substitutions with the exception of a three 
nucleotide (coding for valine) deletion at position 142 and six nucleotide 
duplication in exon 3 (Klimtchuk et al., 2018). It has been shown in vitro 
that the resulting amino acid substitutions destabilize the amyloidogenic 
TTR protein to varying degrees; the variant genotypes dictate distinct 
and often unique clinical manifestations of ATTR amyloidosis. The clinical 
presentation of patients with ATTRv amyloidosis is generally dominated 
by cardiac symptoms referred to as familial amyloidotic cardiomyopathy 
(FAC), or neurological symptoms referred to as familial amyloidotic 
neuropathy (FAP). Additionally, TTR amyloid can deposit in other tissues 
such as the gastrointestinal tract, lungs, and carpal ligament, generating 
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a wide range of clinical signs and symptoms (Cornwell et al., 1995; 
Gertz et al., 2015; Planté-Bordeneuve & Said, 2011).  
 The first widely studied TTR variant is the V30M mutant. The 
nomenclature for TTR protein variants denotes the amino acid 
substitutions in the mature protein ultimately involved in the clinical 
disease. For example, V30M indicates that a valine residue is substituted 
by a methionine residue at amino acid position 30 of the mature TTR 
protein (Sipe et al., 2016). The clinical presentation of patients with 
ATTR V30M is usually a length-dependent sensory peripheral 
neuropathy (Dwulet & Benson, 1983). This mutation was first described 
in Portuguese kindreds with FAP (Andrade, 1952). Large clusters of 
patients with V30M ATTR amyloid have been reported in Portugal 
(Saraiva, Costa, & Goodman, 1983), Japan (Tawara, Araki, Toshimori, 
Nakagawa, & Ohtaki, 1980), Sweden (Sousa, A., Andersson, Drugge, 
Holmgren, & Sandgren, 1993), and Brazil exhibiting a wide range of 
penetrance, disease onset age, rate of progression, and organ 
involvement (Finsterer et al., 2019). Another very common variant is 
V122I TTR mutant. This mutation is found almost exclusively in patients 
of West African descent (Gorevic, Prelli, Wright, Pras, & Frangione, 
1989; Jacobson et al., 2016). The mutant allele frequency in self-
identified African-Americans is 3.5% (Jacobson et al., 2016). Patients 
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with the V122I mutation typically present with late-onset cardiac 
disease and progressive heart failure, having a median survival of 
approximately 5 years from diagnosis (Ando et al., 2013; Connors et 
al., 2009).  
Like in V122I TTR amyloidosis, sporadic wild-type TTR amyloid 
deposits mostly affect the heart (Gertz et al., 2015; Merlini & 
Westermark, 2004). Patients usually present with symptoms of 
congestive heart failure, diastolic dysfunction, conduction disease, and 
infiltrative cardiomyopathy due to the deposition of wild-type TTR 
amyloid in both the ventricular and atrial walls of the heart 
(Westermark, Sletten, Johansson, & Cornwell, 1990). The disease 
primarily affects older Caucasian men (Ng, Connors, Davidoff, Skinner, 
& Falk, 2005) prompting the moniker senile systemic amyloidosis (SSA) 
and senile cardiac amyloidosis (SCA) (Cornwell et al., 1995; Merlini & 
Westermark, 2004). ATTRwt amyloidosis is clinically challenging to 
diagnose due to the non-specific clinical presentation of heart failure 
with preserved ejection fraction (HFpEF) (González-López et al., 2015). 
In addition, the correct diagnosis has required accurate interpretation 
of echocardiography or cardiac magnetic resonance imaging which is not 
readily available at all healthcare facilities (Maurer, 2015). Recently, 
however, non-invasive radionuclide bone scintigraphy with technetium-
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labeled bisphosphonates has been shown to be diagnostic of cardiac 
ATTR amyloidosis without confirmatory heart biopsies, providing a non-
invasive path to identification of ATTR amyloid cardiomyopathy 
(Gillmore et al., 2016). The median survival from disease diagnosis until 
death is, similar to V122I ATTR amyloidosis, less than 5 years (Connors 
et al., 2011). In autopsy studies of men over the age of 80, 
approximately 25% have amyloid deposits in the heart due to wild-type 
TTR (Tanskanen et al., 2008; Westermark, Bergström, Solomon, 
Murphy, & Sletten, 2003). In many of these cases, amyloid 
cardiomyopathy was not suspected pre-mortem. Consequently, ATTRwt 
amyloidosis is thought to be under-recognized (Falk, 2012; Grogan et 
al., 2016; Liu, P. P. & Smyth, 2016; Sawyer & Skinner, 2006). Data 
derived from the increasingly sensitive diagnostic tools projects 10% of 
patients of patients with heart failure over the age of 65 years are at 
risk for the ATTRwt amyloid cardiomyopathy (Ruberg, Grogan, Hanna, 
Kelly, & Maurer, 2019). 
 
1.4 Genetic factors in transthyretin amyloidosis 
Although the clinical course of disease varies among individuals 
with different pathologic mutations, significant variation among 
individuals with the same mutation has generated interest in other 
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disease modifiers. Studies suggest that non-coding variants in the cis-
regulatory region of the TTR gene may modify or promote disease 
expression in ATTRv disease (Olsson et al., 2010; Polimanti, Di 
Girolamo, Manfellotto, & Fuciarelli, 2013; Soares et al., 2004). The 
transcriptional effects of non-coding variants in individuals with the 
same coding mutation could explain variable genetic penetrance, age at 
onset, disease severity, and sex differences. Studies contrasting 
Swedish and Portuguese carriers of the TTR V30M mutation reveal lower 
disease penetrance and later onset in the Swedes (Sousa, A. et al., 
1993). Subsequently, Soares et al. (2004) investigated variations within 
the TTR genes and their flanking sequences in patients with and without 
the V30M mutation, describing polymorphisms in the untranslated 
regions that could potentially modulate onset of symptoms. Another 
study identified a SNP (rs62093482) located in the 3’ untranslated 
region (UTR) of the TTR gene associated with a significant difference in 
allele frequency between carriers and control in the Swedish V30M group 
(Olsson et al., 2010). The authors hypothesized that this SNP may play 
a role in down-regulating TTR gene expression through a miRNA-
dependent pathway, inducing a partial silencing effect on the expression 
of the TTR V30M allele. Downregulation of transcription could account 
for the low penetrance and older age of onset observed in the Swedish 
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V30M carriers by limiting the TTR substrate for amyloid formation. Since 
the regulatory function of miRNA leads to mRNA degradation, one would 
expect the V30M carriers with the 3’ UTR polymorphism to have lower 
levels of plasma TTR. While not directly assessed by Olsson et al., a 
previous study showed significantly lower circulating TTR levels in V30M 
carriers compared to healthy controls in the Swedish population (Suhr 
et al., 1998). However, a follow-up study of the 3’ UTR SNP rs62093482 
demonstrated no effect on downregulating expression of the variant 
allele (Norgren, Hellman, Ericzon, Olsson, & Suhr, 2012). 
Polimanti et al. analyzed the TTR gene and its surrounding regions 
in different human populations to look for genetic variants and their 
functional impact employing the 1000 Genomes Project database 
(Polimanti et al., 2013). The 1000 Genomes Project is an international 
research consortium dedicated to sequencing the genomes of 1,000 
volunteers from multiple populations worldwide (Europe, East Asia, 
South Asia, West Africa, and the Americas) to better understand genetic 
influences on health and disease (1000 Genomes Project Consortium et 
al., 2010). They found significant ethnic differences in the TTR gene 
between African and non-African individuals that may modify expression 
of the complex TTR-related amyloidosis pathogenesis.  
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 The first large study to assess non-coding genetic changes of the 
TTR gene in a well-characterized ATTRwt cohort identified associations 
of polymorphisms with disease, age at onset, and survival was 
conducted (Sikora et al., 2015). The hypothesis proposed that cis-acting 
regulatory regions in the TTR gene may modulate clinical progression in 
ATTRwt disease. The study involved sequencing of four non-coding 
regulatory regions and the four coding TTR exons in an ATTRwt cohort 
of 108 Caucasian males with cardiomyopathy due to wild-type TTR 
deposition contrasted with 118 age, sex, and race-matched controls 
(Sikora et al., 2015). In these two cohorts, three of eleven identified 
common variants significantly associated with the clinical parameters of 
age at diagnosis and survival from onset. In particular, the SNP 
rs3764479, an A to G transition at position 31,589,862 in the NCBI 
genome build GRCh38.p12 and 2,015 bp upstream of the transcription 
start site, was associated with later age of onset of ATTRwt disease. In 
contrast, the SNP rs72922940, an A to G transition at position 
31,590,735 in the NCBI genome build GRCh38.p12 and 1,142 bp 
upstream of the transcription start site, closely associated with ATTRwt 





1.5 Transcriptional regulation of the TTR gene 
The TTR gene is located on chromosome 18 and is approximately 
10 kb in length. The gene is composed of 4 exons, 3 introns, and a 
regulatory proximal promoter region (Sakaki, Yoshioka, Tanahashi, 
Furuya, & Sasaki, 1989; Sasaki, Yoshioka, Takagi, & Sakaki, 1985; 
Tsuzuki, Mita, Maeda, Araki, & Shimada, 1985) (Figure 1.3). The 
structures of the TTR gene and resultant protein are highly conserved 
between human and mouse species, with over 82% homology in the 
coding sequence and 91% homology in the amino acid sequence (Costa, 
Lai, & Darnell, 1986).  
The transcriptional regulation of the mouse TTR gene has been 
extensively studied. Initial studies using transient transfection assays in 
HepG2 cells showed that a 300 bp region upstream of the cap site was 
sufficient to drive transcription. Interestingly, inclusion of 3,000 bp of 
upstream sequence increased transcription by 10-fold suggesting an 
element between -3,000 and -300 bp contained an important activation 
region in the mouse TTR gene (Costa et al., 1986). This transcriptional 
activity was not seen in HeLa cells suggesting that the proximal 
promoter element is partly responsible for the hepatic cell and species-
specific expression of the TTR gene. Deletion experiments narrowed the 






































































































































































































































































































































































































promoter region (between -108 and -151 bp) and a more distal 
enhancer region (between 1.6 and 2.15 kb) upstream of the start codon 
proved important for mouse TTR gene transcription (Costa et al., 1986). 
Subsequent studies by the same group targeted the active region of the 
enhancer to a 100 bp sequence between 1.96 and 1.86 kb upstream of 
the mRNA cap site. Interestingly, the sequence contains at least three 
nuclear protein binding sites, two of which bound proteins only found in 
hepatocytes and another that bound a transcription factor (activator 
protein-1 or AP-1) found in HeLa and spleen cells (Costa, Lai, Grayson, 
& Darnell, 1988a). These three binding sites were also reported in the 
enhancer region of the α1-antitrypsin (α1-AT) gene, suggesting a 
shared and coordinated role of trans-acting factors in the regulation of 
hepatocyte-specific gene transcription (Grayson, Costa, Xanthopoulos, 
& Darnell, 1988). Additional studies in the proximal promoter region of 
the TTR and α1-AT genes described previously unknown hepatocyte-
enriched transcription factors HNF3 and HNF4 (Costa, Grayson, & 
Darnell, 1989). 
Although relatively poorly studied, the human TTR gene is 
reported to contain binding sites for transcription factors responsible for 
hepatocyte-specific expression in the mouse TTR gene, such as HNF1, 
HNF3, HNF4, and C/EBP through homology search in the 5’ flanking 
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regulatory region of the gene (Sakaki et al., 1989). A further upstream 
region was also identified that may act as an estrogen-responsive 
element (ERE) between -3406 and -3392 bp where binding of 17 beta-
estradiol (E2) drove transcription in luciferase reporter assays as 
confirmed by EMSA and supershift assays (Martinho, Santos, & 
Gonçalves, 2013). 
 
1.6 Hypothesis and aims 
In the studies presented in this dissertation, I sought to 
understand how disease-associated SNPs in the non-coding regions of 
the TTR gene affect its transcription. My hypothesis is that the presence 
of a nucleotide polymorphism affects the binding of one or more 
transcription factors regulating transcription of the transthyretin gene, 
modifying production of transthyretin protein and altering the 
pathogenesis and progression of disease. I believe that the SNP 
rs3764479, previously associated with later onset of disease in the 
ATTRwt population studied at Boston University Amyloidosis Center, 
disrupts transcription factor binding in the promoter of the transthyretin 
gene resulting in lower levels of serum transthyretin levels, leading to 
later age of disease onset. In this work, I aim to identify transcription 
factors that bind at the site of the rs3764479 SNP and study the 
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interaction of transcription factor binding to wild-type sequence and 
rs3764479-containing sequence using mobility shift assays. 
 Finally, in an effort to understand the noncoding genetic influences 
on the clinical expression of ATTR amyloid disease, I will examine 
differences in the promoter region of the TTR gene among V122I ATTR 













CHAPTER 2. MATERIALS AND METHODS 
 
2.1 Cell culture experiments 
HepG2 cells (ATCC HB-8065) were grown and maintained in 75 cm2 
flasks (Corning, Corning, NY) with Dulbecco’s modified Eagle medium 
(DMEM) containing 4.5 g/L glucose, L-glutamine, and sodium pyruvate 
(Corning) supplemented with 10% fetal bovine serum (FBS; Gibco, 
Carlsbad, CA) and 100 units/mL Penicillin-Streptomycin (Gibco). The 
cells were cultured in a SANYO MCO-18AIC (UV) CO2 incubator (Tokyo, 
Japan) at 37°C and 5% CO2 with media replacement every 48 hours 
until 70%-90% confluent. For passaging confluent cells, medium was 
aspirated off and the cells were washed with phosphate-buffered saline 
(PBS) (Thermo Fisher Scientific, Waltham, MA); detachment of the cells 
was accomplished with the addition of 4 mL of 0.25% trypsin-EDTA 
(ethylenediaminetetraacetic acid) (Gibco) and incubation at 37°C for 5 
minutes. To the solution containing detached cells, 4 mL of fresh growth 
media was added and this cell suspension was equally distributed into 






2.2 Electrophoretic mobility shift and supershift assays 
HepG2 cell nuclear extract served as the source of nuclear 
proteins for use in the electrophoretic mobility shift assays. The nuclear 
extract was isolated by trypsinizing and collecting cells from 4 confluent 
75 mm2 (T75) flasks (Corning, Corning, NY). The cells were centrifuged 
at 400 x g for 5 minutes, the supernatant aspirated, and the cell pellet 
incubated for 10 minutes on ice in a lysis buffer containing 20 mM 
HEPES, pH 7.4, 10 mM KCl, 2 mM MgCl2, and 0.5% IGEPAL CA-360. The 
cells were subsequently centrifuged at 200 x g for 5 minutes and the 
pellet washed twice with 800 µL of lysis buffer not containing IGEPAL 
CA-360; each wash was followed with a 400 x g 5-minute centrifugation 
step. After the second wash, 100 µL nuclear extract buffer containing 
20 mM HEPES, pH 7.4, 10 mM KCl, 2 mM MgCl2, 500 mM NaCl was 
added to the nuclei pellet and incubated for 10 minutes with occasional 
vortexing. The sample was then centrifuged at 20,000 x g for 15 minutes 
and the supernatant was carefully collected in a pre-chilled 1.5 mL 
microcentrifuge tube. The protein concentration was measured with a 
Pierce bicinchoninic acid (BCA) Protein Assay Kit (Thermo Fisher 
Scientific). To prepare 7 mL of BCA working reagent, 140 µL of Reagent 
B was added to 6860 µL of Reagent A. Bovine serum albumin (BSA) 
standard solutions at concentrations of 2,000, 1,500, 1,000, 750, 500, 
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250, 125, and 25 µg/mL were prepared for use in the BCA assay for 
protein concentration measurement by appropriate dilution of a 1 
mg/mL working or stock solution of BSA (Thermo Fisher Scientific) with 
nuclear extraction buffer; nuclear extraction buffer alone served as a 
blank in the assay. Triplicates of the following samples were added to a 
96-well plate (Corning, Corning, NY): 10 µL of each of the 8 BSA 
standard concentrations, as well as a 1:10 dilution of nuclear extract. 
Two hundred µL of the working reagent, as defined above, was then 
added to each well and mixed by shaking of the plate for 30 seconds. 
The plate was covered and incubated at 37ºC for 30 minutes after which 
it was cooled to room temperature and sample absorbance measured at 
562 nm on a SpectraMax M5 reader (Molecular Devices, San Jose, CA); 
nuclear extract was stored in a -80ºC freezer at a concentration of 5 
µg/µL until further use. 
Short DNA probes with the wild-type or variant (rs3764479) 
sequences, as well as the consensus sequences for the transcription 
factors including HNF1, HNF3a, and HNF3b, ONECUT3, and JUN that 
were predicted to bind or have disrupted binding at the TTR proximal 
promoter site due to the presence of the ATTRwt disease-associated 
single nucleotide polymorphism, rs3764479, were ordered from Thermo 
Fisher Scientific. The nucleotide sequences used for all probes are shown 
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in Table 2.1. The sense and antisense strands were annealed by 
heating them together to 90ºC in 1x oligo buffer containing 10 mM tris 
base, pH 8.0, 1 mM EDTA, 50 mM NaCl and slowly letting them cool. 
Biotin labeling of the wild-type and variant strands was performed with 
Pierce Biotin 3’ End Labeling Kit (Pierce, Waltham, MA) prior to annealing 
the sense and antisense strands. One µM of the sense or antisense oligo 
was incubated at 37ºC with for 30 minutes in a 50 µL reaction with 1X 
TdT Reaction Buffer, 0.5 µM Biotin-11-UTP, 0.15 U/µL TdT. To halt the 
reaction, 2.5 µL of 0.2 M EDTA was added. The sense and antisense 
oligos were then annealed post-labeling as described above. 
Twenty µL binding reaction with RNase-free water, 1x binding 
buffer, 50 ng/µL poly dI-dC, 2.5% glycerol, 0.1 mM EDTA from 
ThermoFisher Scientific Lightshift Chemiluminescent EMSA kit were 
combined with DNA probes (2 pmol final concentration) on ice. Following 
the addition of 10 µg nuclear extract, the reaction mix was allowed to 
stand on ice for 20 minutes to allow binding reactions to equilibrate. 
Five µL 6x DNA gel loading dye (Thermo Fisher Scientific) was added to 
each sample, mixed by pipetting, and carefully loaded onto a 6% TBE 
gel (1.0 mm thick, 12 well). Electrophoresis was performed using a TBE 
running buffer (45 mM Tris, 45 mM boric acid, 1 mM EDTA), pH 8.3. The 




Table 2.1. Probe names and sequences used for EMSA and 
supershift assays to assess binding interaction between 
HepG2 nuclear extract and the rs3764479 SNP. Probes are listed 
in the 5’ to 3’ direction. The HNF1, HNF3a, and HNF3b consensus 
sequences were designed for study with the rs72922940 SNP. 
Underlined base represents the location of the SNP (rs3764479 for 
WT, rs3764479, ONECUT3, JUN, and semi-scramble; rs72922940 for 
HNF1, HNF3a, and HNF3b consensus). Bolded bases represent areas 
that were changed from the wild-type sequence to either include the 
indicated transcription factor consensus sequence binding site or to 
not include the binding site for the semi-scramble sequence. 
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minutes and subsequently electrophoresed for an additional 90 minutes 
after the sample loading. 
When electrophoresis was complete as indicated by the dye front 
reaching 1 cm from the bottom of the gel after about 90 minutes, gels 
were removed from the cassette and the samples were 
electrophoretically transferred onto a Biodyne (Fort Wayne, IN) B Pre-
Cut Modified Nylon membrane (0.45 µm) at 4ºC and 200 mA for at least 
30 minutes using TBE buffer. When transfer was complete, protein and 
nucleotide samples captured and separated on the membrane were 
cross-linked under UV light for 10 minutes in ImageQuant LAS 4000 (GE 
Healthcare Life Sciences, Marlborough, MA). The next step involved 
gently shaking the membrane in 20 mL Nucleic Acid Detection Blocking 
Buffer (Pierce Chemiluminescent Nucleic Acid Detection Module, Thermo 
Fisher Scientific) for 15 minutes, followed by gentle agitation in 
Conjugate Buffer (1:300 dilution of Stabilized Streptavidin-Horseradish 
Peroxidase Conjugate to Nucleic Acid Detection Blocking Buffer) for 15 
minutes, and four successive washes of the membrane with 1X Wash 
Buffer by gentle shaking for 5 minutes and replacement of the buffer. 
Finally, the membrane was gently shaken in 30 mL of Substrate 
Equilibration Buffer (Thermo Fisher Scientific) for 5 minutes. While 
shaking, Chemiluminescent Substrate Working Solution (Thermo Fisher 
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Scientific) was prepared by adding 6 mL Luminol/Enhancer Solution 
(Thermo Fisher Scientific) to 6 mL Stable Peroxide Solution. The 
membrane was removed from the Equilibration Buffer (Thermo Fisher 
Scientific) and placed on an imaging tray with plastic wrap underneath. 
The Substrate Working Solution (Thermo Fisher Scientific) was poured 
onto the membrane covering the entire membrane and allowed to stand 
for 5 minutes without shaking. Excess solution was removed by blotting 
the membrane edge with a paper towel; imaging was accomplished by 
exposing the membrane with the chemiluminescence imaging setting on 
the ImageQuant LAS 4000 (GE Healthcare) for 1-minute intervals until 
the bands were clearly visualized. The ImageQuant TL software was 
used to perform semi-quantitative analysis of the bands by 
densitometric measurement. 
Competition EMSAs were performed by adding the appropriate 
excess fold of unlabeled DNA oligo to the binding reaction as described 
above before addition of the nuclear extract. The subsequent steps are 
the same as described above. Supershift assays were performed by 
adding 0.4 µg of the appropriate antibodies to the reaction mix after the 





2.3 Serum TTR measurements 
Serum TTR concentrations were measured at the Boston Medical 
Center Pathology Department Laboratory using an immunoturbidimetric 
assay with coefficients of variation (CV) < 5.5% (Abbott Laboratories, 
Abbott Park, IL) (Hanson et al., 2018). Patient and control serum 
samples were stored at ≤ -20°C prior to analysis or assessed 
immediately as part of the standard of care for a clinical workup. 
 
2.4 Genomic DNA isolation 
Patient whole blood samples, obtained from the Boston University 
Amyloidosis Center repository with the approval of the Institutional 
Review Board at the Boston University Medical Campus in accordance 
with the Declaration of Helsinki, were centrifuged at 400 x g for 10 
minutes in an Eppendorf Centrifuge 5804 R. The buffy coat layer (800 
µL) was removed and stored in 1.5 mL Ambion RNAlater solution (Life 
Technologies, Carlsbad, CA) at -80°C until genomic DNA extraction was 
performed at a later date. 
Genomic DNA (gDNA) was isolated from 200 µL of the buffy 
coat/RNAlater sample using a Qiagen QIAamp DNA Mini Kit according to 
the manufacturer’s Blood and Body Fluid Spin protocol. The samples 
were thawed and centrifuged at 400 x g for 10 minutes and the RNAlater 
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solution was aspirated and replaced with RNase-free water (Qiagen). 
Twenty µL of a 28 µg/mL solution of Ambion Proteinase K (Thermo 
Fisher Scientific) was pipetted to the bottom of a 1.7 mL Eppendorf 
microcentrifuge tube and overlayed with 200 µL of the buffy 
coat/RNAlater sample followed by 200 µL of Buffer AL. The combined 
solution was mixed by pulse-vortexing for 15 seconds and incubated at 
56ºC for 10 minutes in a Fisher Scientific Isotemp Thermal Mixer. 
Following a brief centrifugation to remove any condensate on the tube 
lid, 200 µL of 100% ethanol (Pharmco, Brookfield, CT) were added; the 
sample was mixed by pulse-vortexing for 15 seconds and this step was 
followed by another short spin. The mixture was then carefully added to 
a QIAamp Spin Column (in a 2 mL collection tube) without wetting the 
rim and centrifuged at 6,000 x g (8,000 rpm) for 1 minute. If the lysate 
did not pass completely through the column, the sample was centrifuged 
at 20,000 x g for 1 minute. The column was placed on a new 2 mL 
collection tube and 500 µL of Buffer AW1 was added without wetting the 
rim and centrifuged at 6,000 x g for 1 minute. The flow-through was 
discarded and 500 µL of Buffer AW2 was added to the column and 
centrifuged at 20,000 x g for 3 minutes. If there was any flow-through 
visible between the walls of the column and the collection tube, the flow-
through was discarded and the column was centrifuged again at 20,000 
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x g for 3 minutes. The column was subsequently placed on a new 1.5 
mL microcentrifuge tube and 150 µL of RNase-free water was added 
directly onto the membrane; this setup was allowed to stand at room 
temperature for 5 minutes. The gDNA was eluted off by centrifuging the 
sample at 6,000 x g for 1 minute; a Thermo Scientific Nanodrop Lite 
Spectrophotometer was used to assess the quality and concentration of 
the extracted material with measurements of absorbance at 260 and 
280 nm. The gDNA was stored at -20°C until required for study. 
 
2.5 Genetic study populations 
Patients referred to the BU Amyloidosis Center Clinic for 
evaluation between 2004 and 2019 who tested positive for TTR-V122I 
based on serum isoelectric focusing and TTR genotyping, showed 
histologic evidence of amyloid by Congo red staining a biopsy or TcPyP 
scanning, and cardiac involvement comprised the V122I cardiac group. 
Cardiac involvement was defined as interventricular septal or 
inferolateral wall thickness less than the upper limit of normal on 
echocardiogram imaging and serum brain natriuretic peptide levels 
(BNP) > 100 pg/mL. A second study set, referred to as the V122I non-
cardiac group, consisted of patients who tested positive for of TTR-
V122I, but did not have serum biomarker or echocardiographic evidence 
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of cardiac amyloid involvement. Lastly, a cohort of patients who were 
seen at Boston Medical Center with cardiomyopathy not attributed to 
cardiac amyloid disease (with normal TTR genotype) were chosen for 
comparative analyses and designated as the cardiomyopathy non-V122I 
group. Informed consent for data and sample collection were obtained 
from the patients upon initial visit with approval of the Boston University 
Medical Campus Institutional Review Board (IRB) in accordance with the 
Declaration of Helsinki. Clinical, laboratory and echocardiographic data 
were obtained from an IRB-approved database of amyloidosis patients. 
All three groups were age-, race-, and gender-matched as closely as 
possible. The numbers of patients in the V122I cardiac, V122I non-
cardiac, and cardiomyopathy non-V122I groups were 36, 8, and 22, 
respectively. 
 
2.6 Transthyretin gene sequencing and genotyping 
Based on previous reports describing disease associated genetic 
risk factors in ATTRv and ATTRwt, we chose an area of the TTR proximal 
promoter to study. The region of interest spanned a length of 2 kb and 
was located immediately upstream of the TTR transcription start site at 
positions 31,589,760 to 31,590,831 (Assembly GRCh38.p13) on 
chromosome 18. The DNA region targeted for study was amplified by 
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polymerase chain reaction (PCR) using forward (5’-
CACAGGGTCTACAAGAGATG-3’) and reverse (5’-
CAGCAAGTTTGGTTCTGTC-3’) primers. The reactions were set up using 
a Qiagen Taq PCR Master Mix kit with final concentrations for the 
reaction buffer of 1x and 0.25 µM for each primer (forward and reverse) 
in a final volume of 25 µL. Amplifications were performed by activating 
the Taq Polymerase at 95ºC for 5 minutes followed by 20 cycles of: 
melting at 95ºC for 30 seconds, annealing at 62ºC for 45 seconds with 
a decrease of 0.5ºC per cycle, and extension at 72ºC for 90 seconds. An 
additional 25 cycles of melting at 95ºC for 30 seconds, annealing at 
52ºC for 45 seconds with a decrease of 0.5ºC per cycle, and extension 
at 72ºC for 90 seconds were performed followed by a final extension for 
10 minutes at 72ºC. 
PCR products were electrophoretically analyzed on 1.5% agarose 
gels prepared by boiling 1.5 g of LE Agarose (Fisher Scientific) in 100 
mL 1x TAE Buffer (40 mM Tris-acetate, 1 mM EDTA) until all the agarose 
was dissolved. Ten µL of 10 mg/mL ethidium bromide (Fisher Scientific) 
was added and mixed gently once the agarose solution had cooled. Once 
suitable for handling, the medium was poured into a gel box casting tray 
and solidified at room temperature for at least 30 minutes. The gel, 
containing 5 µL of PCR product per well, was run at 100 V for 1 hour 
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and the bands were visualized in the ImageQuant LAS 4000 instrument 
using the UV fluorescence setting with auto exposure time. For 
assessment of PCR product size and quantity, 5 µL of GeneRuler 1kb 
DNA Ladder (Thermo Fisher Scientific) was also electrophoresed in the 
far right and left lanes of the gel. 
For nucleotide sequencing, PCR products were purified using the 
Applied Biosystems ExoSAP-IT PCR Product Cleanup Reagent (Thermo 
Fisher Scientific); ~60 ng/5 µL of PCR product was added to 2 µL of the 
reagent. Purified samples were submitted to Genewiz (Cambridge, MA) 
for nucleotide sequencing in both forward and reverse directions with 
internal sequencing primers (5’-CAGCAAGTTTGGTTCTGTC-3’ and 5’-
TCCTGAGCTCAAGCAATC-3’) used to provide coverage for the entire 2 
kb region. 
 
2.7 Functional prediction online database tools 
Transcription factor binding site disruption due to the presence of 
single nucleotide polymorphisms (SNPs) was predicted by using an 
online database of transcription factor binding data called JASPAR 
(http://jaspar.genereg.net/) (Fornes et al., 2020). This database 
contains transcription factor binding profiles derived from published and 
experimentally determined sources modeled as matrices that can then 
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be converted into Position Weight Matrices (PWMs) to be used for 
scanning genomic sequences. A 44-base sequence 
(GAACTTCCAAATATTTATGATTCATAGCCAGAGAAAAGGCTCTC) with the 
17th nucleotide in this sequence being the position of rs3764479 was 
used to search for all candidate proteins (transcription factors) predicted 
to bind to this sequence in the JASPAR database with a relative profile 
score threshold of 75%. The 44-base sequence length was chosen to 
allow for adequate binding of important transcription factors and 
increase the likelihood of detecting transcription factor binding 
important for the transcription of the TTR gene. Since this type of 
analysis has high sensitivity but very low selectivity, each individual 
result was checked manually for expression in the liver and for its 
potential role in the regulation of liver-specific genes. Transcription 
factors that were not expressed in the liver were excluded from this 
study. To further validate that transcription factors predicted to bind to 
this sequence and chosen for study were likely to be functionally 
competent in the human genome, the MAPPER database 
(http://genome.ufl.edu/mapperdb/) was used (Riva, 2012). This 
database relies on hidden Markov models built from experimentally 
determined transcription factor binding sites with the purpose of 
increasing sensitivity and specificity of transcription factor binding. 
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Results from both the MAPPER and JASPAR database queries agreed 
with respect to the specific transcription factors predicted to bind at the 
sequence containing rs3764479 and chosen for study in this dissertation 
work. 
 
2.8 Genetic statistical analyses 
The nucleotide sequence chromatograms were analyzed using the 
Mutation Surveyor software (SoftGenetics, State College, PA). 
Reference sequence files were generated from a GenBank sequence file 
that was downloaded from the NCBI website containing the entire TTR 
gene and its upstream elements; these data included the dbSNP archive 
for designating any known single nucleotide polymorphisms detected in 
the sequenced study samples. Any nucleotide changes were 
automatically detected by the software with the default settings and 
verified manually in all samples both in forward and reverse directions. 
The SNPs identified in the patient sequences were analyzed further with 
the Haploview software (Barrett, 2009). Single marker association tests 
were performed using the chi square test for independence and p-value 
comparing allele frequencies between cases and controls for each SNP. 
Multiple testing bias was corrected for the association using permutation 
testing in the Haploview program with 1,000 permutations. Haplotypes 
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were computed among the SNPs that were different between the 
population groups and population frequencies were calculated by 
Haploview. Variant groups were manually identified and haplotype 
frequencies calculated. The haplotype association tests were performed 
on the set of blocks including all the SNPs specified for the comparison 
between the three groups. Association tests for were verified in the 
PLINK Regression analyses to find correlations between SNPs and 
clinical features were computed with PLINK (Purcell et al., 2007). The 
age difference between the V122I cardiac and V122I non-cardiac group 
were corrected for by using age as a quantitative covariate in the model 








CHAPTER 3. DIFFERENTIAL BINDING OF LIVER-SPECIFIC 
TRANSCRIPTION FACTORS IN THE TRANSTHYRETIN GENE DUE 
TO PRESENCE OF GENETIC RISK FACTORS (RS3764479 AND 
RS72922940) RELATED TO ATTRWT AMYLOIDOSIS 
3.1 Background 
Wild-type transthyretin (ATTRwt) amyloidosis is a sporadic protein 
misfolding disease that is primarily seen in elderly Caucasian men (Falk 
& Skinner, 2000; Kisilevsky, 1991; Merlini & Westermark, 2004). The 
reason for the gender disparity seen in this disease is not well 
understood and likely to be multifactorial with differential transcriptional 
regulation of the TTR gene possibly being a contributory factor. The 
disease presents with symptoms of congestive heart failure (HF) due to 
deposition of the wild-type plasma protein transthyretin (TTR) fibrils in 
the myocardial tissue of the heart (Connors et al., 2016; Siddiqi & 
Ruberg, 2018). Due to its symptom overlap with congestive heart failure 
resulting from other etiologies, the prevalence of ATTRwt amyloidosis is 
likely to be underestimated clinically. Under-recognition of the disease 
is further exacerbated by the fact that definitive diagnosis, until 
recently, required tissue biopsy proof, which can be problematic in 
elderly patients. As the aging population expands and the recognition of 
ATTRwt amyloidosis grows, the burden of the disease will undoubtedly 
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challenge healthcare providers. Currently, there are no validated 
biomarkers to track disease progress nor are there any specific 
treatments (Mankad & Shah, 2017). 
Serum TTR levels have been investigated as a potential biomarker 
of disease in both wild-type and inherited forms of TTR-associated 
amyloidoses. In several studies, serum TTR levels have been 
consistently lower than normal concentrations in patients with ATTRv 
amyloidosis (Benson & Dwulet, 1983; Buxbaum, J., Koziol, & Connors, 
2008; Connors, Gertz, Skinner, & Cohen, 1984; Saraiva et al., 1983; 
Shoji & Nakagawa, 1988; Skinner et al., 1985; Westermark et al., 
1985). A meta-analysis from these studies demonstrated that serum 
transthyretin levels in 154 ATTRv patients were significantly lower than 
healthy controls (168 vs. 220 µg/mL, p = 0.005) (Buxbaum, J., Anan, 
& Suhr, 2010). In ATTRwt patients, lower baseline serum TTR levels (at 
a cutoff of <18 mg/dL) have been found to be associated with shorter 
survival and worsening cardiac function (Hanson et al., 2018).  
It is not clear, however, whether lower levels of serum TTR is an 
indication of protein deposition in tissue or due to altered gene 
expression. Recently, single nucleotide polymorphisms (SNPs) located 
in the non-coding regions of the TTR gene were shown to be significantly 
associated with increased risk for ATTRwt disease (Sikora et al., 2015). 
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In hereditary forms of TTR amyloidosis, there has also been interest in 
the genetic regulation of the transthyretin gene arising from 
observations of different clinical phenotypes exhibited by patients with 
the same disease-causing mutation. Prior investigations focused on 
populations with the V30M mutation (Iorio et al., 2017; Soares et al., 
2004), the second most prevalent TTR mutation in the world. 
The expression of the TTR gene, located on chromosome 18, in 
hepatocytes is controlled by a highly conserved proximal promoter 
region that spans approximately -50 to -190 base pairs upstream of the 
transcription start site as well as an enhancer region that has been well 
characterized in the murine genome (Costa et al., 1986; Yan, Costa, 
Darnell, Chen, & Van Dyke, 1990). Key transcription factors binding at 
these sites have been identified in the mouse gene including HNF1, 
C/EBP, HNF3, and HNF4 (Costa, Grayson, Xanthopoulos, & Darnell, 
1988; Costa, Lai, Grayson, & Darnell, 1988b; Costa et al., 1989; 
Grayson et al., 1988; Sakaki et al., 1989). There is a large degree of 
homology between the mouse and human TTR genes in both coding and 
regulatory regions likely indicating similar transcriptional control 
(Wakasugi, Maeda, Shimada, Nakashima, & Migita, 1985).  
In previous work performed by our lab on a large (n > 100) 
ATTRwt cohort, two SNPs in the promoter of the TTR gene, denoted 
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rs3764479 (2,015 bp upstream of the transcription start site) and 
rs72922940 (1,142 bp upstream of the transcription start site), were 
found to be associated with the clinical variables, age at onset and/or 
survival from onset. Thus, it was hypothesized that these genetic 
variants influence the expression of TTR and progression of ATTRwt 
amyloid disease through disrupted binding of hepatocyte transcription 
factors in this regulatory region of the TTR gene. Preliminary reporter 
studies in HepG2 cells induced with pHAGE lentiviral constructs 
containing 2 kb of the TTR gene promoter with either rs3764479 or 
rs72922940 revealed lower reporter expression compared to the wild-
type promoter (Hanson, 2017). Based on these data, our hypothesis for 
the current studies is that the TTR gene in the TTR-associated 
amyloidosis is dysregulated at the transcriptional level by the presence 
of disease-associated variation in the proximal promoter element, non-
coding variations that may play a role in disease pathobiology. 
 
3.2 In silico predictions of functional transcription factor binding 
disruptions due to rs3764479 using online databases 
As described above, the TTR gene structure and regulation has 
been studied previously but not in the context of transthyretin-related 
amyloidoses. To understand whether the presence of non-coding SNP 
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rs3764479 leads to altered expression of the gene, a search for potential 
transcription factor disruptions was undertaken using online databases 
of transcription factor binding profiles. The open-access JASPAR 
database catalogues transcription factor profiles curated and derived 
from published collections of experimentally determined binding sites 
(Mathelier et al., 2014). This database allowed for a quick and 
comprehensive approach to identify transcription factors potentially 
important for transthyretin expression whose binding is altered by the 
SNP rs3764479. 
The sequences used for transcription factor identification involved 
44 base pairs (with the location of the SNP rs3764479 at position 17) to 
try to include important flanking sequences for transcription factors. 
Using the JASPAR database, with a relative profile score threshold of 
75%, I identified 134 transcription factors specific to the wild-type 
sequence when compared to the sequence containing rs3674479. 15% 
(20/134) of the group were reported to have liver-specific roles. In 
contrast, there were 46 transcription factors specific to the rs3674479 
sequence compared to the wild-type sequence. We focused on the wild-
type specific transcription factors as we were interested in disruptions 
of existing regulatory transcription factor binding and not creation of 
new transcription factor binding sites in the presence of the SNP. To 
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limit further studies to interactions that are most likely to have a 
functional significance in vivo, the list of transcription factors was 
narrowed down to five (Table 3.1) that were selected based on their 
expression in the liver and their role in regulation of liver-specific genes.  
 
3.3 Electrophoretic mobility shift assays evaluating binding 
dynamics of liver-specific transcription factors to short 
nucleotide sequences 
 A study exploring the associations of various SNPs with 
hippocampal atrophy in families with Alzheimer’s Disease found a 
significant association of rs3764479 with bilateral medial temporal 
atrophy (Cuenco et al., 2011). Since transthyretin inhibits the 
production of amyloid β protein, the authors postulated that increased 
TTR levels may protect patients from Aβ protein accumulation. The 
association between rs3764479 and hippocampal atrophy suggests a 
role for non-coding sequence regulation of transthyretin expression and 
protein levels. However, there is no reported evidence that rs3764479 
SNP disrupts transcription factor binding. My hypothesis is that the 
rs3674479 SNP disrupts binding of the HNF family of transcription 
factors known to affect transcriptional regulation in hepatocytes, 
























Table 3.1. List of transcription factors selected for study, 
their functions, and predicted binding site sequences. 
Transcription factors were selected from a list of wild-type specific 
transcription factors that differed between wild-type and rs3764479 
SNP sequences on the JASPAR database at a relative threshold of 
75%. Black arrows indicate binding locations potentially disrupted 
by specific SNP.  
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the transthyretin protein. To evaluate whether the presence of the 
rs3764479 SNP disrupted the binding of the transcription factors 
identified previously through the JASPAR database, the electrophoretic 
mobility shift assay (EMSA) method was used as a simple yet robust 
technique to study a wide range of binding conditions (Hellman & Fried, 
2007). The assay is highly sensitive with biotin-labeling, allowing for 
detection of small amounts of protein and nucleic acid complexes. In 
addition, the technique allows for comparison of binding affinities and 
quantification by densitometric analysis (Fried, 1989). 
Short nucleic acid probes were designed for binding studies with 
HepG2 nuclear extract proteins as shown in Table 2.1. Nuclear extracts 
from HepG2 cells were used as this hepatocellular carcinoma cell line 
would contain the transcription factors necessary for TTR gene 
transcription (Castell, Jover, Martínez-Jiménez, & Gómez-Lechón, 
2006). The first comparison was whether nuclear extract proteins 
preferentially bound the wild-type or rs3764479 probes. With equal 
amount of HepG2 nuclear extract and biotin-labeled wild-type or 
rs3764479 probe, a higher signal was observed in the protein-probe 
complex band of wild-type compared to rs3764479 (Figure 3.1A Lanes 
1 vs 7). Plotting the signals from wild-type and rs3764479 protein-



















Figure 3.1. Electrophoretic mobility shift assay showing 
higher protein-probe complex signal with wild-type 
oligonucleotide compared to rs3764479 probe. Panel A shows 
the EMSA gel with the protein-probe complex bands at the top and 
free probe bands at the bottom. The labeled wild-type and rs3764479 
variant probes were competed against unlabeled rs3764479 or wild-
type probes, respectively, at fold excesses of 200, 100, 50, 25, or 10. 
Panel B shows the mean relative signal intensities of the protein-
probe complex bands from three separate assays with and error bars 
representing the SEM showing significantly higher wild-type signals 
compared to the rs3764479 sequence. The results of the WT and 
variant signals (n = 3) were analyzed by unpaired two-tailed t-test. 
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protein-probe complex (Figure 3.2).  
Competition between the wild-type and rs3764479 probes was 
also assessed in Figure 3.1A (lanes 2 – 6 & 8 – 12) employing 
varying amounts of excess fold of unlabeled competitor. As expected, 
higher concentrations of unlabeled competitor resulted in lower signal 
from the protein-probe complex band (lane 2 vs 6 & lane 8 vs 12). This 
comparison showed that the wild-type and rs3764479 oligomers are 
able to compete off each other and that the wild-type oligomer seemed 
more robust in competing off the mutant oligomer compared to the 
reverse experiment in which the mutant oligomer showed a weaker 
effect on wild-type oligomer binding (Figure 3.1B). These results were 
consistently observed at 10-, 25-, 50-, and 100-fold excess 
concentrations of unlabeled to labeled probe with significant (p <0.05) 
differences noted for the 10- and 50-fold excess competitions. Signals 
were normalized to their respective labeled probe with nuclear extract 
only signal.  
To investigate whether the observed protein-probe complex 
contained transcription factors whose binding might be disrupted by the 
presence of rs3764479, competition EMSAs were performed using 
probes containing consensus sequences for HNF1, HNF3a, HNF3b, 










Figure 3.2. Protein-probe complex signal with wild-type 
sequence compared to rs3764479 sequence. Plots of 
chemiluminescence signal of the protein-probe complex band from 
HepG2 nuclear extract with either wild-type or rs3764479 sequence 
labeled probes. Plots are from three separate gels with the WT and 
rs3764479 signals of each gel connected by a line. Signal intensity 
measured by densitometric analysis (n = 3). Paired t-test showed a 





















Figure 3.3. Competition EMSA showing successful competition 
of HNF1, HNF3b, ONECUT3, and JUN consensus sequence 
probes to the wild-type probe. The competition was between 
labeled wild-type probe with various unlabeled transcription factor 
consensus probes and semi-scramble control. Panel A shows a 
representative gel with protein-probe complex bands at the top of the 
gel and free probe bands at the bottom. Panel B shows the relative 
signal intensities of the protein-probe complex bands from the 
transcription factor consensus competitions with HNF3a signal 





















Figure 3.4. Competition EMSA showing successful competition 
of HNF1, HNF3b, ONECUT3, and JUN consensus sequence 
probes to the rs3764479 probe. Electrophoretic mobility shift 
assays of competition between labeled rs3764479 probe with various 
unlabeled transcription factor consensus probes and scramble 
control. Panel A shows a representative gel with protein-probe 
complex bands at the top of the gel and free probe bands at the 
bottom. Panel B shows the relative signal intensities of the protein-
probe complex bands from the transcription factor consensus 




Successful competition of unlabeled transcription factor consensus 
sequence probe and diminished signal of labeled probe-protein complex 
would suggest the presence of that particular transcription factor in the 
protein-probe complex. Degree of competition reflects the certainty of 
the presence of the transcription factor in the protein-probe complex.  
Lane 1 of both Figure 3.3A and Figure 3.4A show a free probe 
band without the HepG2 nuclear extract. Lane 2 of both figures then 
show the appearance of a protein-probe complex once the nuclear 
extract is added to the mix indicating the presence of a protein complex 
that recognizes the wild-type or rs3764479 containing probe, 
respectively. Lanes 3 & 4 of both figures then show successful 
competition of the labeled WT in Figure 3.3A and rs3764479 in Figure 
3.4A in the presence of a 100-fold excess of unlabeled WT (lane 3) and 
rs3764479 (lane 4). Four of the five transcription factor consensus 
probes were able to compete off the labeled wild-type and rs3764479 
probes at a fold-excess of 100 with the exception of HNF3a (lanes 5 - 
9). The protein-probe complex signals dropped to less than 10% of the 
no-competitor signal with the exception of the HNF3a consensus probe 
(Figures 3.3B and 3.4B). 
To understand whether the competition of the transcription factor 
consensus sequence differs significantly between wild-type and 
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rs3764479-bound protein-probe complexes, different fold-excesses of 
unlabeled transcription factor consensus probes ranging from 10 to 100 
were used and analyzed densitometrically as before. Interestingly, 
nuclear extract showed stronger binding to the mutant sequence 
compared to the wild-type sequence in the presence of the HNF1 
(Figure 3.5A); in contrast, when HNF3b was present, the reverse effect 
was noted, i.e. nuclear proteins appeared more tightly associated with 
the wild-type sequence (Figure 3.5B). Nuclear extract proteins did not 
show a clear binding preference towards wild-type or mutant sequences 
when ONECUT3 or JUN consensus competitor probes were present 
(Figure 3.5C and 3.5D). 
To assess the identity of the HepG2 proteins bound to the TTR 
promoter sequences in the shifted bands observed by EMSA, supershift 
assays were performed separately using antibodies to the transcription 
factors being studied. The supershift assay is a simple additional step to 
the EMSA protocol that can provide specific evidence for the presence 
of a suspected transcription factor. Supershift of the protein-probe 
complex band after the addition of a specific antibody to a suspected 
protein in the complex can provide strong evidence for the interaction 
of that protein to the probe being used -- although lack of a shift does 









Figure 3.5. Preferential binding of HNF1 transcription factor 
to the rs3764479 sequence and HNF3b binding to the wild-
type sequence. Fold gradient competition EMSAs of unlabeled 
consensus sequence probes against either labeled wild-type (WT) or 
rs764479 variant (rs479) probes. The signal intensities represent the 
mean from three different gels with the error bars representing the 
SEM. HNF1 showed significant preferential binding to the rs3764479 
sequence at 10-fold while conversely, HNF3b showed significant 
preferential binding to the wild-type sequence at 25-fold excess. 
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The addition of a monoclonal anti-HNF1 antibody revealed a supershift 
when the HNF1 consensus probe was used as a control, but no supershift 
was observed when the wild-type or mutant TTR probe were used 
(Figure 3.6). In the presence of antibody against HNF3b, the control 
HNF3b consensus probe showed a supershift but the original shifted 
band location was difficult to visualize (Figure 3.7). Similar to the HNF1 
supershift assay, there were no supershifts that were observed when 
the wild-type or the mutant probes were used with the monoclonal anti-
HNF3b antibody.  
 
3.4 Dual luciferase cotransfection assay for evaluation of 
C/EBPα, C/EBPβ, and HNF1 transcription factor binding in 
HepG2 cells 
Previous in silico investigation in our lab identified potential 
disruptions of the bindings sites of transcription factors C/EBPα, C/EBPβ, 
and HNF1 at the site of the SNP rs72922940. To test whether these 
transcription factors play a role in the regulation of the TTR gene at the 
site of disease-associated, HepG2 liver carcinoma cells were 
cotransfected with a plasmid expressing one of the three transcription 
factors of interest (HNF1, C/EBPα, C/EBPβ) and a plasmid expressing 





Figure 3.6. HNF1 transcription factor does not show a 
supershift of the protein-probe complex between HepG2 
nuclear extract and probes with and without rs3764479. HNF1 
supershift assay gel depicting the expected supershift of the protein-
probe complex in the presence of HNF1 antibody but not TTR antibody 
when the protein-probe complex contains the HNF1 probe. The same 
supershift, however, is not seen when the protein-probe complex 






Figure 3.7. HNF3b transcription factor does not show a 
supershift of the protein-probe complex between HepG2 
nuclear extract and probes with and without rs3764479. 
HNF3b supershift assay gel depicting the supershift of the protein-
probe complex in the presence of HNF3b antibody but not TTR 
antibody when the protein-probe complex contains the HNF3b probe. 
The same supershift, as with HNF1, is not seen when the protein-
probe complex contains the WT or rs3764479 probes.  
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TTR promoter with the rs72922940 variation. To control for transfection 
efficiency, Promega’s Nano-Glo Dual-Luciferase Reporter Assay System 
was used in which a vector expressing the NanoLuc luciferase enzyme 
is also transfected into the cells can be measured separately from the 
firefly luciferase enzyme. Fluorescence data were recorded and the 
firefly signal was normalized to the NanoLuc luciferase signal. Each 
reading signifies a triplicate measure from three different transfection 
experiments. 
Interestingly, the C/EBPα and C/EBPβ transcription factors 
appeared to drive down the expression of the firefly luciferase regardless 
of the presence of the rs72922940 polymorphism (Figure 3.8). HNF1, 
on the other hand, did not show a significant effect on the gene 
expression compared to the C/EBPα and C/EBPβ. The relative reporter 
activity in the presence of the HNF1 transcription factor was slightly 
increased with SNP vs WT although not significantly so. Expression of 
the luciferase was significantly increased in the rs72922940 variant 
vector compared to the wild-type.  
 
3.5 Summary and conclusions 
 In this chapter, I sought to explore the transcriptional regulation 





Figure 3.8. Increased transcription of TTR gene with 
rs72922940 variant and decreased expression with C/EBPα 
and C/EBPβ transcription factors. Results of three separate dual-
luciferase reporter assay in HepG2 experiments showing relative 
luciferase signal to the wild-type with empty vector alone. The 
vectors used in this experiment were TTR promoter driven luciferase 
reporter with and without rs72922940, constitutively active C/EBPα, 
C/EBPβ, HNF1 transcription factors, and Nano-Glo luciferase vector 
to control for transfection efficacy. The transcription factors C/EBPα 
and C/EBPβ significantly reduced transcription whereas HNF1 had no 
effect in both the WT and rs72922940 driven promoters. 
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rs3764479 and rs72922940. I started by selecting liver-specific 
transcription factors whose binding is predicted to be disrupted by the 
rs3764479 SNP. Then, I studied the interaction between HepG2 nuclear 
extract proteins and short oligonucleotide probes containing the site of 
the SNP rs3764479 using electrophoretic mobility shift assays. Starting 
by exploring the binding affinities of the nuclear extract proteins to the 
wild-type and rs3764479 probes, there was a lower signal from the 
protein-probe complex band of the rs3764479 sequence probe 
compared to the wild-type, suggesting that the presence of SNP might 
affect transcription factor binding. 
In further EMSA studies with transcription factor consensus probes 
with sequences that closely match the binding site for our transcription 
factors of interest, four of the five transcription factor probes were able 
to compete strongly. HNF3a showed less competition, suggesting that it 
is not present in the protein-probe complex and was not studied further. 
Of the four other transcription factors (HNF1, HNF3a, ONECUT3, and 
JUN), fold-gradient EMSAs demonstrated stronger binding of nuclear 
extract proteins to the rs3764479 sequence compared to the wild-type 
sequence in the presence of the HNF1. HNF3b, on the other hand, 
showed the reverse effect with stronger binding of proteins to the wild-
type sequence compared to the rs3764479 sequence. ONECUT3 and 
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JUN both did not demonstrate stronger binding to either the wild-type 
or the rs3764479 sequence. Supershift assays to verify the presence of 
the transcription factors of interest did not show a shift of the protein-
probe complex in the presence of the HNF1 or HNF3b antibodies in either 
the wild-type or rs3764479 probes. The shift was, however, seen when 
the protein-probe complex contained the consensus sequence probe for 
the transcription factor of interest.  
 Lastly, I explored the effect of rs72922940, another SNP that was 
associated with disease in the ATTRwt cohort, in a cell-based system 
using a dual-luciferase reporter assay. More specifically, expression 
levels were studied with promoters containing either the wild-type 
sequence or containing the rs72922940 variant in the presence of 
abundant C/EBPα, C/EBPβ, or HNF1 transcription factors. Expression 
levels were higher in the vector driven by the promoter with the 
rs72922940 variant compared to the wild-type promoter without excess 
transcription factors. Cotransfecting with either C/EBPα or C/EBPβ 
expressing vector drove down the expression of the luciferase 
significantly in both the WT and rs72922940 vectors whereas the HNF1 
expressing vector had no effect. 
 I postulated that the SNPs associated with ATTRwt disease 
exerted their effect through the transcriptional control of the TTR gene. 
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In this chapter, I studied these effects by identifying potential 
transcription factor involved in the expression of the TTR gene at the 
site of the rs3764479 and rs72922940 SNPs followed by EMSAs and 
supershift assays. The EMSA studies showed stronger signal of HepG2 
nuclear proteins with the wild-type sequence compared to the 
rs3764479 sequence. In competition EMSAs to understand the effect of 
the SNP on transcription factor binding, there was stronger affinity of 
the nuclear proteins to the mutant sequence with the HNF1 probe 
whereas there was stronger affinity to the wild-type sequence with the 
HNF3b probe. However, the presence of these particular proteins were 
not seen in supershift assays with either the wild-type or rs3764479 
SNPs. Lastly, whether the transcription factors C/EBPα, C/EBPβ, and 
HNF1 were involved in the regulation of the TTR gene expression at the 
rs72922940 SNP site was studied using a dual-luciferase reporter 
system. The results showed that the C/EBPα and C/EBPβ transcription 
factors significantly decreased the expression of the reporter with both 
the wild-type and rs72922940 promoters whereas HNF1 seemingly had 









CHAPTER 4. NON-CODING GENETIC DIFFERENCES IN THE 
PROMOTER OF THE TTR GENE IN PATIENTS WITH THE 
AMYLOIDOGENIC V122I TTR MUTATION 
4.1 Background 
Over 100 known hereditary variations have been described in the 
TTR gene that are associated with systemic amyloidosis. Of these, the 
V122I TTR (pV142I) variant in which isoleucine is substituted for valine 
at amino acid position 122 is the most common worldwide (Jacobson et 
al., 1997). The amino acid substitution promotes the dissociation of the 
transthyretin tetramer subsequently leading to deposition of misfolded 
protein primarily in cardiac tissue (Jiang et al., 2001a). It is one of the 
most common genetic causes of hereditary TTR-associated amyloidosis 
that primarily affects individuals of West African descent and found in 
approximately 3.5% of African Americans in the United States (Jacobson 
et al., 2016). The disease is typically diagnosed in the seventh decade 
of life or later with patients presenting with typical signs of congestive 
heart failure and arrhythmias (Rapezzi et al., 2010). The phenotypic 
penetrance is unclear, but clearly increases with age and may be as high 
as 80% in men who carry the mutation (Buxbaum, J. et al., 2010; 
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Jacobson et al., 2011; Quarta et al., 2015) but it is not known why some 
individuals with the variant do not develop symptoms while others do. 
The differences in clinical course of disease among individuals with 
the same amyloidogenic variant has been a longstanding topic of study. 
Particularly, the difference in clinical disease progression between the 
Swedish and Portuguese populations with the V30M variant has sparked 
interest in the possibility of other disease modifiers that affect disease 
pathogenesis. Studies in these populations have explored the 
hypothesis that non-coding variants in the regulatory regions of the TTR 
gene may be associated with disease development (Olsson et al., 2010; 
Polimanti et al., 2013; Soares et al., 2004). Recently, our lab reported 
the presence of variants in the non-coding region of the TTR that 
associate with the development of wild-type ATTR amyloidosis (Sikora 
et al., 2015). These findings supported non-coding variant regulation of 
TTR gene transcription and thus play a role in disease progression in 
both the wild-type and hereditary ATTR amyloidosis. To our knowledge, 
the non-coding regulatory regions in individuals with V122I ATTR 
amyloid has not been studied. We hypothesized that there are non-
coding genetic variants in the TTR gene among patients with hereditary 
V122I TTR that associate with phenotypic expression of cardiac 
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amyloidosis. To explore this hypothesis, we studied V122I TTR 
genopositive patients with and without evidence of cardiomyopathy. 
 
4.2 Cohort Characteristics 
To study whether there were differences in the non-coding region 
of the TTR gene, we identified older (age ≥ 59) African American 
patients referred to the BU Amyloidosis Center Clinic for evaluation 
between 2004 and 2019 who were heterozygotic carriers of the V122I 
TTR allele based on serum isoelectric focusing and subsequent TTR exon 
genotyping. Patients were divided into cardiac involvement or no cardiac 
involvement. No cardiac involvement (V122I non-cardiac) was defined 
as any combination of the following: interventricular septal OR 
inferolateral wall thickness < upper limit of normal on echocardiographic 
imaging, AND plasma B-type natriuretic peptide levels (BNP) < 100 
pg/mL OR plasma troponin I < upper limit of normal. The remainder of 
patients were defined as cardiac involvement (V122I cardiac). Lastly, a 
cohort of race, age, and sex matched patients with heart failure not 
attributed to cardiac amyloidosis disease (with normal TTR genotype, 
acquired through separate study) were chosen for comparative analyses 
and designed as the cardiomyopathy non-V122I control group. All three 
groups were age-, race-, and sex-matched as best as possible (Table 
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4.1). The relatively smaller group of V122I non-cardiac group were 
younger than either the V122I cardiac or the non-V122I groups as well 
as being comprised of mostly women. The majority of patients in all 
three groups self-identified as Black with 2 individuals self-identifying 
as White the V122I cardiac group and another 2 individuals identifying 
as White in the V122I non-cardiac group. Cardiac biomarkers for the 
three groups are shown in Table 4.2.  
 
4.3 Levels of serum TTR and densitometric analysis of serum 
TTR variants 
Transthyretin protein circulates throughout the body as a stable 
homotetramer. The protein is produced primarily by the liver where its 
expression is under the control of the promoter that is being studied in 
this section. As such, I postulate that the effect of the differences in the 
non-coding regulatory region in the TTR gene between our groups might 
affect the levels of serum protein. Furthermore, depending on whether 
the non-coding changes were on the same DNA strand as the coding 
V122I or not, I postulated that the amount of wild-type and variant 







































































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   


































































































































































































































the non-coding variant was present on the wild-type allele, then the 
relative proportion of wild-type protein vs. variant protein could be 
lower, favoring misfolding and amyloid formation. This could be 
manifest as lower circulation concentrations. To study this further, 
serum TTR concentrations of the patients at initial presentation in our 
three groups were measured and it was found that the TTR level was 
significantly lower in V122I cardiomyopathy group compared to the 
V122I non-cardiomyopathy and non-V122I cardiomyopathy groups, 
even though age between these groups was similar (Figure 4.1).  
To further understand the expression of TTR and the potential 
effects of genetic changes in the regulatory region, I performed 
densitometric analysis of serum isoelectric focusing gels that were done 
at the initial visit of the patients with the V122I mutation as well as 
other patients with different coding mutations in the TTR gene. The 
concept behind this analysis was that since gel band density would 
correspond to relative subunit abundance (wild-type vs variant), a lower 
intensity band migrating to the expected site of V122I might provide 
further insight into differences in total circulating TTR concentration. As 
can be seen in Figure 4.2, mutant protein levels are consistently lower 






Figure 4.1. Serum TTR levels of the cohorts of the non-coding 
genetic study as measured by an immunoturbidimetric assay. 
Levels are from initial evaluation at the Boston University Amyloidosis 
Center. The serum TTR levels of the V122I cardiac group were 
significantly lower than the V122I non-cardiac and cardiomyopathy 
non-V122I groups at initial presentation. There was no significant 
difference in serum TTR levels between the V122I non-cardiac and 





Figure 4.2. Ratio of serum variant TTR level to wild-type TTR 
level as measured by densitometry from serum isoelectric 
focusing gels. The V122I mutant is amyloidogenic with a 
cardiocentric phenotype. The V30M mutation is also an 
amyloidogenic mutation that can affect many organ systems. The 
T119M mutation is a non-amyloidogenic mutation. The E42G 
mutation is amyloidogenic whereas the H90N mutation is non-
amyloidogenic. The E42G/H90N variants are a double mutation 
inherited on the same chromosome seen in one kinship. Ratio of less 
than 1 suggest lower serum concentration of the variant protein 
compared to the wild-type protein as seen in most of the groups 
assessed but a ratio of greater than, as seen in two of the E42G/H90N 
variant group, suggests higher serum concentration of variant protein 




double mutant which showed higher expression compared to the wild-
type protein in two individuals. This compound mutation (substitution of 
glutamic acid with glycine at amino acid position 42 and substitution of 
histidine with asparagine at position 90) has only been described in one 
Italian kindred where the H90N mutation is considered non-
amyloidogenic (Skare et al., 1994). The difference is not significant, 
however, due to only three individuals with this particular double 
mutation being studied. These findings suggest that lower circulating 
TTR concentrations derive, in part, from lower circulating variant 
protein. 
 
4.4 Non-coding genetic changes TTR-V122I cardiac 
amyloidosis 
The focus of this study was on the 2 kb region upstream of the 
transcription start site including the promoter as previously studied in 
ATTRwt cohort by our lab. This region has been postulated to be 
important in the regulation of the TTR gene expression although has 
been shown to not be vital to expression in the mouse promoter. PCR 
amplification of the region followed by subsequent Sanger sequencing 
revealed the presence of 8 SNPs that differed among the three studied 











Figure 4.3. Single nucleotide polymorphisms (SNPs) identified 
in the cohorts studied with base pair positions, reference and 
variant alleles, as well as reported and observed minor allele 
frequencies both in our cohort and previously reported in 
ATTRwt cohort. The SNPs were identified by the Mutation Surveyor 
program and manually verified. The reported MAF are from the 
African American population of the 1000 Genomes project. Location 
of the SNPs on chromosome 18 of the genome assembly GRCh38.p12 





closely with the frequencies reported in the literature in the African 
American population with the exception of rs955705399 which showed 
a higher than reported minor allele frequency in the study group of this 
work. All variations were within Hardy-Weinberg equilibrium (HWE) in 
the groups. Haplotypes were determined for the identified 8 SNPs with 
HaploView and PLINK programs (Figure 4.4). The darker shade 
represents close linkage between particular SNPs. Interestingly, the 
SNPs rs13381522 and rs58616646 were very closely linked with very 
little recombination between them despite not being the closest in 
proximity (Figure 4.4 & 4.6). 
In comparing the V122I cardiomyopathy and V122I non-
cardiomyopathy groups, the SNP rs955705399 was associated with 
disease with a Chi square of 6.974 and a p-value of 0.0083. After age-
adjusted covariate analysis, the p-value stayed significant at 0.0149. In 
addition, the haplotype GCGACGT, as shown in Figure 4.5, showed a 
significant association with disease with a Chi square of 4.301 and p-
value of 0.0381. In contrast, the SNP rs72922940 was significantly 
associated with disease (Chi Square value of 3.936 & p-value of 0.0473) 
in the comparison between the V122I cardiomyopathy and non-V122I 











Figure 4.4 SNPs showing variance between the V122I cardiac 
and cardiomyopathy non-V122I groups and their relative 
locations (A). The shaded map represents the level of linkage 
disequilibrium (LD) between the SNPs by r2 value with darker shade 
representing stronger linkage. Panel B shows the most common 








Figure 4.5. Single marker and haplotype association tests of 
polymorphisms between V122I cardiac and cardiomyopathy 
non-V122I groups showing significant association of SNP 
rs72922940 with disease. (A) Single nucleotide polymorphism 
association test results between the V122I cardiomyopathy and non-
V122I cardiomyopathy groups along with the associated allele tested, 
its frequencies in the case (V122I cardiomyopathy) and control (non-
V122I cardiomyopathy) groups, the Chi square value, and the p-
values. (B) Most common haplotypes in the two compared groups 
with their overall frequencies as well as frequencies in the two groups 











Figure 4.6. SNPs showing variance between the V122I cardiac 
and V122I non-cardiac groups and their relative locations (A). 
The shaded map represents the level of linkage disequilibrium (LD) 
between the SNPs by r2 value with darker shade representing 
stronger linkage. Panel B shows the most common haplotypes and 







Figure 4.7. Single marker and haplotype association tests of 
polymorphisms between V122I cardiac and V122I non-
cardiac groups showing significant association of SNP 
rs955705399 with disease. (A) Single nucleotide polymorphism 
association test results between the V122I cardiac and V122I non-
cardiac groups along with the associated allele tested, its frequencies 
in the case (V122I cardiomyopathy) and control (non-V122I 
cardiomyopathy) groups, the Chi square value, and the p-values. The 
SNP rs955705399 shows significance with a p-value of 0.0083 (B) 
Most common haplotypes in the two compared groups with their 
overall frequencies as well as frequencies in the two groups with 
correspond Chi square and p-values. The haplotype GCGACGT is 




 In sequencing the regulatory region of the TTR gene, an 
interesting region with multiple dinucleotide repeats with differing 
number of repeats were suggested by our collaborator, Dr. Daniel 
Jacobson, to potentially play an important regulatory function. Table 
4.3 shows the number of dinucleotide repeats in the three regions that 
are close in proximity that display these repeats in the three groups. 
The preliminary reading of the dinucleotide region show a different 
distribution of repeats in the three regions with each of the three groups 
having individuals with different combinations of dinucleotide repeats. 
The Sanger sequencing result chromatograms, however, were not 
completely clean as both the forward and reverse reads showed 
overlapping background signals (Figure 4.8).  
 
4.5 Summary and conclusions 
In the studies described in this chapter, the upstream promoter of 
the TTR gene in individuals with the common TTR-V122I mutation was 
investigated to try to better understand the effect of non-coding genetic 
changes in the expression of the transthyretin gene and protein. A group 
of patients who had the TTR-V122I mutation with symptoms of cardiac 
amyloidosis disease, patients who had the TTR-V122I mutation without 







Table 4.3. Numbers of different dinucleotide repeat 
combinations seen in the three groups of the V122I TTR 
genetic study. Each number represents the repeat in strand of an 
individual. The combination corresponds to the number of repeats in 
each of the three sections of the following sequence: 
(AC)nATGCGCGT(GC)n(AC)nAT(AC)3. The most common 
combinations were the 6-4-8 and 6-4-9 with varying number of 
repeats across all regions. Repeat numbers were determined by 






















Figure 4.8. Chromatogram from a sequencing of 
an individual in the dinucleotide repeat region 
showing overlapping peaks. Each peak corresponds 
to a base while lower overlapping peaks indicate either 




but with cardiomyopathy not from amyloid disease were identified. 
Differences in the regulatory region of the TTR gene between the two 
groups with V122I but with and without disease manifestation could, in 
part, explain why individuals with the same coding mutation show 
different disease progression and phenotypic variation. 
In studying these groups, V122I cardiac group exhibited the 
lowest circulating TTR levels compared to the two other groups. To 
explore whether wild-type and mutant proteins TTR proteins are 
expressed to the same extent, serum isoelectric focusing gels done in 
patient serum samples with different coding mutations were analyzed. 
It was found that the mutated protein quantities were less than the wild-
type protein in V122I, V30M, T119M, and H90N patients. In the few 
patients with the double E42G/H90N mutation, there was an observable 
but not significant increase in mutant protein to wild-type protein ratio. 
In the promoter region of the TTR gene, 8 SNPs that differed 
between the three groups were identified. Of these, the SNP 
rs955705399 was significantly associated with cardiac disease between 
the V122I cardiac and V122I non-cardiac groups and the significance 
remained when adjusted for the age difference between the groups with 
a p-value of 0.0149 using the Chi-square test of independence in the 
Haploview program. In addition, the haplotype GCGACGT, 
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corresponding to the alleles of the SNPs of the order rs3764479, 
rs13381522, rs1667246, rs955705399, rs74571421, rs3764477, and 
rs58616646 was also significantly associated with disease between the 
two V122I groups (p-value of 0.0381). When comparing the two 
cardiomyopathy groups with and without the V122I mutation, the 
variant allele for the rs72922940 SNP was significantly associated with 
the non-V122I group with a p-value of 0.0473. Haplotypes between 
these two groups did not show significant associations. 
Lastly, an interesting dinucleotide repeat region identified in the 
described study cohorts. This region is postulated to be important in the 
regulation of the downstream gene and, potentially, protein expression. 
The distribution of the dinucleotide repeats in this region among the 
three groups shows a wide range of variability that, in part, may lead to 
different transcriptional regulation of the TTR gene. 
This chapter detailed the study of the non-coding genetic changes 
in the promoter region of patients with V122I ATTR amyloid. The 
differences in TTR levels and the ratio of variant to wild-type protein 
based on serum isoelectric focusing gels were compared with notable 
differences observed. Furthermore, SNP and dinucleotide region 
differences were noted between the three groups studied that may have 
an impact in TTR gene transcription as well as circulating TTR levels. 
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Our preliminary studies suggest that there are differences in TTR 
expression in the presence of several SNPs that may influence 
pathogenesis of the disease, potentially contributing to the phenotypic 
variability seen in patients with the V122I mutation through altered 
































CHAPTER 5. DISCUSSION 
 
5.1 Role of rs3764479 and rs72922940 on the transcriptional 
regulation of the TTR gene 
 
5.1.1 Transcriptional regulation of the TTR gene and transcription 
factor selection 
The role of non-coding SNPs in the development and progression 
of TTR amyloidosis has not been studied well. However, I believe that it 
is an important process to study as the presence of regulatory 
polymorphisms has been shown to play a role in human disease (Bosma 
et al., 1995; Kulozik, Bellan-Koch, Bail, Kohne, & Kleihauer, 1991). 
Evidence for transcriptional control of the TTR gene in disease pathology 
has been demonstrated in a study that found upregulated TTR mRNA 
and protein levels in neurons of Alzheimer’s disease model mice 
compared to neurons of controls (Li et al., 2011). Furthermore, small 
molecules recently approved by the FDA for the treatment of hereditary 
transthyretin amyloidosis have shown that degradation of the TTR 
mRNA in hepatocytes and subsequent protein production either halt or 
reverse disease progression and result in improved clinical outcome 
(Adams et al., 2018; Benson et al., 2018). These data taken together 
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suggest that mRNA level as a result of transcriptional regulation of the 
TTR gene may have a significant contribution to disease progression in 
transthyretin-associated amyloidoses. In Chapter 3, I hypothesized that 
the SNPs (rs3764479 and rs72922940) previously identified to be 
associated with ATTRwt amyloidosis in a cohort of ATTRwt amyloidosis 
patients (Hanson, 2017) modified transthyretin gene expression and 
inhibited disease progression. The SNP rs3764479 is an A to G transition 
located at position 31,589,862 (2,015 bp upstream of the transcription 
start site) on chromosome 18 (build GRCh38.p12) whereas the SNP 
rs72922940 is an A to G transition located at position 31,590,735 (1,142 
bp upstream of the start site) on chromosome 18. The minor allele 
frequencies of these SNPs can vary greatly in different populations as 
seen in Figure 4.3. While these frequency differences between 
populations are likely to be a result of the geographical separation, the 
significant associations of rs72922940 and rs3764479 with ATTRwt 
disease and delayed onset of disease in the ATTRwt cohort, respectively, 
in an age-, sex-, and ethnicity-matched cohort of 226 individuals lead 
me to believe that these SNPs may have a functional role in ATTRwt 
disease progression. The sample size in the study of non-coding genetic 
variations in the ATTRwt and matched control was determined to be 
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sufficient to detect a SNP association with a large effect with the Genetic 
Power Calculator tool (Hanson, 2017; Purcell, Cherny, & Sham, 2003). 
In studies investigating the expression of the mouse TTR gene, it 
was found that a highly conserved region in the proximal promoter 
region (between 108 and 151 upstream) and a more distal enhancer 
region (between 1.96 kb and 18.86 kb upstream) were needed to 
achieve endogenous levels of TTR transcription (Costa et al., 1988b). 
Although the SNPs rs3764479 and rs72922940 are not found in the 
regions that were shown to be important for murine TTR expression, 
they could still potentially modify the rate of transcription of the TTR 
gene. To study this further, I identified transcription factors whose 
binding would be disrupted by the presence of the rs3764479 SNP using 
the online JASPAR database. The potential binding factor disruption by 
the SNP rs72922940 are not discussed in this work due to the data being 
reported by Hanson (2017) in her dissertation. To ensure inclusion of 
transcription factor bindings, a 44 base pair sequence was used with the 
SNP position at the 17th base pair. Using a relative score threshold of 
75%, there were 397 transcription factors that were predicted to bind 
to the sequence containing the wild-type allele. In contrast, using the 
same score threshold, the sequence containing the variant allele was 
predicted to contain binding sites for 309 transcription factors. These 
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parameters provide high sensitivity but very low selectivity; while true 
functional binding will most likely be detected, many of the predicted 
binding sites have no function in vivo (Fornes et al., 2020). To narrow 
the potential transcription factor list to more biologically relevant 
targets, I focused on the transcription factors whose predicted binding 
include the position of the SNP rs3764479 and, in addition, are unique 
to the wild-type sequence. This narrowed down the list to 134 
transcription factors that are uniquely predicted to bind the site of the 
wild-type allele for rs3764479. This list was then further narrowed down 
by manually reviewing and selecting transcription factors expressed in 
the liver. This step increased the likelihood of biologic significance for 
the identified transcription factors. The five transcription factors 
subsequently studied were HNF1, HNF3a, HNF3b, ONECUT3, and 
JUN(var.2) (Table 3.1). Aside from ONECUT3, about which there is little 
known, the hepatocyte nuclear factors are well established to be 
important for expression of liver specific proteins such as transthyretin 
(Lau, Ng, Loo, Jasmen, & Teo, 2018). JUN is part of the AP-1 protein 
complex that was also found to be a likely candidate for binding at the 
enhancer region (Costa et al., 1988b). In addition to binding at the 
enhancer region of the mouse TTR gene, AP-1 has also been shown to 
be able to interact with the estrogen receptor and regulate the 
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transcription of many other genes including ovalbumin and insulin-like 
growth factor I (Gaub, Bellard, Scheuer, Chambon, & Sassone-Corsi, 
1990; Umayahara et al., 1994; Webb et al., 1999). The possibility of 
the TTR gene being regulated by a complex involving the estrogen 
receptor and AP-1 protein, potentially playing a role in the gender 
differences observed in ATTRwt disease, made JUN an attractive 
transcription factor choice for further studies. 
 
5.1.2 Electrophoretic mobility shift assays for evaluating binding 
dynamics to wild-type and rs3764479 variant allele sequences 
The predicted binding site disruptions for the transcription factors 
chosen were assessed with the gel electrophoresis mobility shift assay. 
This assay is based on the concept that protein-nucleic acid complex has 
less mobility than the free nucleic acid and is a sensitive method of 
studying protein-nucleic acid interaction (Hellman & Fried, 2007). The 
technique is also very robust and can be used to assess binding 
dynamics of a large range of nucleic acid sizes and proteins. To study 
the binding of the selected transcription factors with rs3764479, I 
designed 26 base pair oligonucleotide probes with the WT or the variant 
allele to provide adequate flanking sequence for binding of the 
transcription factors (Table 2.1). Particularly short probes would be less 
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desirable due to the binding sites for transcription factors being close to 
the molecular ends of the probe. This may potentially result in binding 
that is less specific due to sequence but more due to structural and 
electrostatic effects (Naritsin & Lyubchenko, 1991; Olmsted, Anderson, 
& Record, 1989; Vallone & Benight, 2000). In contrast, particularly long 
probes can contain more binding sites that are non-specific and can also 
give a smaller shift of the protein-probe complex upon electrophoresis 
(Fried, 1989). The HNF1, HNF3a, and HNF3b consensus sequence 
probes were previously designed to assess for binding of transcription 
factors to the SNP rs72922940 and thus are slightly longer (39 base 
pairs). This was considered to not be an issue due to the presence of 
the consensus sequence for their respective transcription factors. The 
ONECUT3 and JUV(var.2) consensus sequences were designed to 
examine the rs3764479 SNP and thus are 26 base pairs long and contain 
the same flanking sequence as the WT and rs3764479 variant probes. 
The semi-scramble control was designed to not contain any transcription 
factor binding site and random nucleotides were chosen for the internal 
region of the probe. However, this is not a true scramble control as the 
first 5 and last 2 nucleotides are the same as the other nucleotide probes 
designed for rs3764479 and the numbers of each base (A/C/G/T) were 
not kept consistent between the control and the wild-type sequence. 
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Potential transcription factor binding to the unchanged nucleotides 
would not be eliminated with the semi-scramble control. However, the 
main part of the probe that contains the location of the SNP and its 
immediate surroundings were randomized to function as a true control. 
 The initial EMSA studies compared the binding of HepG2 cell line 
nuclear extracts to the WT or the variant sequence probes (Figure 3.1 
& Figure 3.2). The extract with either probe showed a protein-probe 
complex near the top of the gel which contains the proteins in the 
nuclear extract that recognize the sequence with and surrounding the 
SNP rs3764479. Since all nucleic acid recognizing proteins show some 
degree of nonspecific binding, excess nonspecific competitor nucleic acid 
was added in the form of the synthetic polymer poly(dI-dC) to maximize 
the specificity of the binding visualized (Lane, Prentki, & Chandler, 
1992). In the same gel, the competition between the wild-type and 
variant sequences were also assessed by adding varying fold excesses 
of the unlabeled probe as this may also provide information about the 
sequence requirements of the transcription factors binding to each 
probe (Varshavsky, 1987). The range of 10- to 200-fold excess allowed 
for good visualization of the binding dynamics as the 10-fold excess still 
showed a clear protein-probe complex band whereas the 200-fold 
excess almost completely eliminated the signal from the protein-probe 
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complex band. Interestingly, in the 25-, 50-, and 100-fold excess lanes 
there were two discernible bands in close proximity in the protein-probe 
complex. The upper band seems to be stable as its density does not 
vary greatly between the lanes whereas the bottom band is very 
sensitive to the fold excess of unlabeled competitor. This may be due to 
the top band representing non-specific binding to the labeled probe and 
the bottom band signaling protein binding specific to the sequence in 
the oligonucleotide probe. Alternatively, the two bands may represent 
the binding of the same protein or protein complex but in different 
conformations. The successful competition of labeled wild-type probe 
with unlabeled variant sequence suggests that the proteins binding to 
these sequences overlap to some degree. This is expected as the wild-
type and variant probes vary in one position and the band intensity 
variance likely stems from difference in transcription factor binding to 
the SNP rs3764479 variant allele. Competition of unlabeled WT to 
labeled WT probe and unlabeled variant to labeled variant probes could 
confirm whether the transcription factors in the HepG2 nuclear extract 
are specific to the probes studied and help determine whether these 
transcription factors bind better to the WT or variant allele probes. The 
competition between the WT and variant allele probes did reveal that 
the protein and labeled WT complex had higher signals than the protein 
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and labeled variant complex at the 50-, 25-, and 10-fold excesses 
(Figure 3.1B). This shows that the variant probe is less efficient at 
competing against the WT probe. This difference may potentially be due 
to weaker binding of the same transcription factor at the site of the SNP 
or due to differences in transcription factor complex that is recognizing 
the two probes as the EMSA technique allows for visualization of proteins 
ranging from small oligopeptides to large transcription complexes with 
varying protein stoichiometries (Hudson & Fried, 1990; Mita, B. C., 
Tang, & deHaseth, 1995). 
 
5.1.3 Electrophoretic mobility shift assays to assess for binding of 
previously identified hepatocyte-expressed transcription factors at the 
site of the SNP rs3764479 
Whether the transcription factors identified previously (HNF1, 
HNF3a, HNF3b, ONECUT3, JUN) through the JASPAR database was 
involved in binding the WT or the variant probes were tested using the 
EMSA technique (Figures 3.3 and 3.4). The initial results with the 100-
fold excess of unlabeled competitor probes showed evidence that the 
HNF3a transcription factor had minimal presence in the protein-probe 
complexes with both the WT and variant probes as illustrated by its 
relatively high signal intensities compared to the intensities of the other 
93 
 
transcription factor competitors (Figures 3.3 and 3.4). The HNF3 
proteins were originally identified as important factors in the liver-
specific transcription of the TTR and α1-antitrypsin genes (Costa et al., 
1989). Since then, they have also been shown to be enriched in other 
tissues such as the lung and pancreas where they are known to activate 
many genes (Liu, J. K., DiPersio, & Zaret, 1991; Paulweber, Sandhofer, 
& Levy-Wilson, 1993; Sawaya, Stripp, Whitsett, & Luse, 1993). 
Interestingly, HNF3a has also been shown to be an important factor in 
the interaction between almost all estrogen receptor-chromatin 
interactions in breast cancer cells (Hurtado, Holmes, Ross-Innes, 
Schmidt, & Carroll, 2011). In the liver, the importance of the HNF3 
transcription factors in the hepatocyte-specific expression of the 
transthyretin and other genes has been demonstrated by the decrease 
in their expression in a hepatoma cell line overexpressing a truncated 
form of the HNF3 proteins without a transactivating domain (Vallet, 
Antoine, Chafey, Vandewalle, & Kahn, 1995).  
 With the HNF3a transcription factor seemingly not being part of 
the proteins recognizing the region of interest, the other transcription 
factors were further assessed with competition EMSA. At a 100-fold 
excess of unlabeled competitor probe concentration, the signal seen in 
the protein-probe complex band was very low for HNF1, HNF3b, 
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ONECUT3, and JUN (<10%) for both the WT and rs3764479 variant 
sequences. The higher signal at 10-fold excess of unlabeled HNF1 probe 
with the variant sequence compared to the WT sequence suggested that 
HNF1 may have a stronger binding to the rs3764479 variant allele 
sequence (Figure 3.5A). The HNF1 transcription factor is involved in a 
variety of metabolic functions in the liver, kidneys, intestines, and 
pancreas islet cells (Mendel & Crabtree, 1991). Rare mutations in the 
gene encoding HNF1 have been shown to cause one type of maturity-
onset diabetes of the young which leads to disrupted secretion of insulin 
(Yamagata et al., 1996). In the liver, HNF1 binding sites have been 
identified in the promoter of many acute phase reactant genes including 
C-reactive protein, albumin, transthyretin, fibrinogen, plasminogen, 
insulin-like growth factor 1, and serum amyloid P-component (Dalmon, 
Laurent, & Courtois, 1993; Leu, Crissey, Leu, Ciliberto, & Taub, 2001; 
Lockwood & Frayling, 2003; Odom et al., 2004; Toniatti, Demartis, 
Monaci, Nicosia, & Ciliberto, 1990; Tronche, Ringeisen, Blumenfeld, 
Yaniv, & Pontoglio, 1997). In addition, findings of significant 
associations of polymorphisms in the HNF1-encoding gene and C-
reactive protein levels suggest that HNF1 may play an important role in 
metabolic and inflammatory pathways (Armendariz & Krauss, 2009). As 
such, it is possible that HNF1 plays a role in the transcriptional regulation 
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of the TTR gene with the site of rs3764479 as one of its potential binding 
regions. 
In the fold excesses experiments with the HNF3b consensus 
probe, the inverse effect was seen with higher signals post-competition 
from the protein-probe complex with the WT sequence compared to the 
rs3764479 variant sequence at the 25-fold excess but not in the 10-fold 
excess (Figure 3.5B). The HNF3b transcription factor, similarly to 
HNF3a, is involved in the transcription of a wide variety genes encoding 
for proteins important for liver function (Samadani & Costa, 1996). 
Interestingly, HNF3b has been shown to be important in blood glucose 
homeostasis (Wang, H., Gauthier, Hagenfeldt-Johansson, Iezzi, & 
Wollheim, 2002). In addition, HNF3b has been demonstrated to be 
essential to the development of the foregut endoderm that gives rise to 
the liver and pancreas (Weinstein et al., 1994). In the pancreatic islet 
cells, HNF3b is thought to be an activator of various other transcription 
factors (Wu et al., 1997). Although the binding sites of HNF3a and 
HNF3b are similar, it is interesting to see that the EMSA competitions 
suggest the presence of HNF3b but not HNF3a. This may indicate that 
the DNA probes used recruit a transcription factor complex that HNF3b 
is a part of but not HNF3a. With ONECUT3 and JUN consensus sequence 
probes, there were no differences in the band intensities of the WT or 
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rs3764479 variant sequence complexes at any of the fold excesses 
tested suggesting that these transcription factors most likely do not bind 
to the region where the SNP rs3764479 is located despite seemingly 
present in the protein complex recognized by the WT and rs3764479 
variant sequences. This may be due to binding of these transcription 
factors to a region of the 26 base pair oligonucleotide probe that does 
not span the region of the rs3764479 SNP despite their predicted 
binding with the online database tools. Another reason that cannot be 
ruled out is that they are present in the protein complex through 
interaction with other transcription factors that recognize the DNA 
sequence but do not participate in the binding directly. 
 
5.1.4 Supershift assays for confirming the presence of transcription 
factors HNF1 and HNF3b in the protein-probe complex with sequence 
with or without rs3764479 
The supershift assay is a modification of the EMSA technique in 
which a specific antibody to a protein can confirm the presence of that 
protein in the protein-probe complex by inducing a shift of the protein-
probe complex band (Holden & Tacon, 2011). The results with the HNF1 
and HNF3b antibodies did not show supershifts in the protein-probe 
complex containing the WT or the rs3764479 sequence (Figures 3.6 
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and 3.7). Although helpful in determining the presence of the suspected 
protein if the supershift is observed, the lack of a supershift does not 
necessarily rule out the presence of the protein in the complex (Hellman 
& Fried, 2007). For example, since the EMSA technique is performed in 
non-denaturing conditions, the epitope that the antibodies recognize 
may be inaccessible to the antibodies. In such a case a supershift will 
not be seen even though the protein that is probed for with the specific 
antibody is present in the complex. Even such a factor as whether the 
antibody is added before or after the protein binds DNA can make a 
difference in a supershift being observed in cases where the epitope is 
on the DNA-binding surface of the protein (Buratowski & Chodosh, 
2001). In the supershift assays with the HNF1 and HNF3b antibodies, 
however, the control supershifts worked as expected resulting in a 
supershift of the protein-probe complex with the specific antibody and 
not with the non-specific antibody to the transcription factor of interest. 
A key difference between the control consensus sequence supershift and 
the WT and rs3764479 variant sequence supershifts is that the 
consensus sequence should theoretically bind to the transcription factor 
it is designed for directly as opposed to the WT or the variant sequence 
probes may induce binding of a transcriptional complex that may include 
more than one protein. In such a case, epitope recognition might be 
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harder and a supershift may not be seen despite the presence of the 
suspected transcription factors. 
 
5.1.5 Dual luciferase cotransfection assay for studying the effects of 
transcription factors C/EBPα, C/EBPβ, and HNF1 on TTR transcription 
in the context of the SNP rs72922940  
The SNP rs72922940 was previously shown to have the strongest 
association with ATTRwt disease in the first genetic study of a large, 
well-characterized ATTRwt cohort (Hanson, 2017). This SNP was 
predicted by online tools is-rSNP and JASPAR to disrupt the binding of 
HNF and C/EBP transcription factors and thereby suspected to be a 
functional variant in ATTRwt disease. The dual luciferase cotransfection 
assay was designed to test the effects of the transcription factors 
C/EBPα, C/EBPβ, and HNF1 in the transcription of the luciferase reporter 
driven by the TTR promoter with and without the SNP rs72922940. The 
transfection efficiency was controlled by a cotransfection with a vector 
expressing a different luciferase to which the signals could be 
normalized. Interestingly, the results showed that C/EBPα and C/EBPβ 
completely drove down the transcription of the TTR promoter driven 
luciferase signal regardless of the presence of the rs72922490 
polymorphism (Figure 3.8). Compared to the HNF transcription factors, 
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which are expressed in a very limited range of tissues, the C/EBP 
transcription factors are more ubiquitously expressed and are known to 
be important in cell cycle control and cell differentiation (Lekstrom-
Himes & Xanthopoulos, 1998). Previous studies with the mouse 
enhancer of the TTR gene showed regions that were likely to be bindings 
sites for C/EBP transcription factors and thus they were thought to be 
important activators of the TTR gene (Costa & Grayson, 1991). Both 
C/EBPα and C/EBPβ have been demonstrated to be expressed highly in 
the liver among other tissue (Cao, Umek, & McKnight, 1991; Chang, 
Chen, Lei, Chen, & Lee, 1990; Katz et al., 1993; Williams, Cantwell, & 
Johnson, 1991). The binding of C/EBPα to numerous gene promoters in 
hepatocytes involved in normal function and tissue injury suggest an 
important role in the regulation of terminal hepatocyte differentiation 
(Chang et al., 1990; Lee, Sauer, Johnson, & Gonzalez, 1997; Ramji & 
Foka, 2002). C/EBPβ mRNA can lead to the production of three different 
isoforms, 38 kDa (LAP*), 35 kDa (liver activating protein or LAP) and 
20 kDa (liver inhibitory protein or LIP) (Descombes & Schibler, 1991). 
The LIP isoform lacks the activation domain that is present in the LAP 
isoform and therefore acts as a repressor by forming non-functioning 
dimer with other members of the C/EBP family (Descombes & Schibler, 
1991). In addition to proteins such as TTR, albumin, and alpha-1 
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antitrypsin, C/EBPα and C/EBPβ were also found to be important in the 
expression of enzymes involved in lipid storage and carbohydrate 
metabolism (Croniger et al., 2001; Lee et al., 1997; Liu, S. et al., 1999; 
Wang, N. D. et al., 1995). The results seen with the dual luciferase assay 
with marked decrease in reporter expression in the presence of C/EBPα 
and C/EBPβ suggests that they are able to bind to a region of the 2 kb 
long TTR promoter and drive down transcription but the lack of 
difference seen between the promoters containing the WT sequence and 
the rs72922940 sequences indicate that the site of rs72922940 is either 
likely not the binding site for the C/EBP proteins or that the presence of 
the variant allele for rs72922940 does not influence C/EBP binding at 
that site. 
In contrast, the HNF1 transcription factor did not have a significant 
effect on the transcription. In comparing the promoters with and without 
the presence of rs72922940, there was a significant increase in the 
transcription of the luciferase signal driven by the promoter with the 
rs72922490 compared to the WT promoter. As mentioned previously, 
HNF1 has been shown to be important in the regulation of number of 
liver specific genes including TTR and the acute phase proteins including 
C-reactive protein (CRP) (Dalmon et al., 1993; Ku & Mortensen, 1993; 
Leu et al., 2001; Toniatti et al., 1990). Its absence in mice leads to 
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hepatic enlargement and dysfunction as well as renal disease (Pontoglio 
et al., 1996). The ability of the HNF family of transcription factors to 
regulate many liver genes is likely due to their ability to recognize many 
similar domains in the promote regions of the target genes. The Nano-
Glo Dual-Luceriferase reporter assay used in the study presented in this 
work allows for rapid and sensitive detection of both the experimental 
and control reporters with two different luciferase enzymes which should 
results in improved data quality by eliminating experimental variability. 
In addition, increased signals with the rs72922940 was also seen by 
Hanson in EMSA using a probe with the wild-type allele and the 
rs72922940 variant allele and HepG2 nuclear extract proteins (2017). 
The observed increase was significant with a p-value of 0.012 with a 
two-sided unpaired t-test. While the EMSA studies with the rs72922940 
SNP was not tested in this work, it highlights the importance of the 
stringent methodology to assess the functional role of such SNPs in the 
context of TTR-associated amyloid pathology. 
   
 
5.2 Non-coding genetic differences in the promoter of the TTR 




5.2.1 Identification of genetic risk factors associated with V122I ATTR 
disease 
The V122I mutation is an amyloidogenic coding mutation seen 
almost exclusively in people of African descent (Jacobson et al., 2016). 
The amino acid substitution leads to unstable tetramers and leads to 
increased formation of the free monomer and subsequently aggregation 
and deposition of the protein in the hearts of individuals with the 
mutation (Jiang, Buxbaum, & Kelly, 2001b). Although all TTR-V122I 
carriers after the age of 65 had evidence of cardiac amyloid deposition 
in a large autopsy study, the clinical course of disease development and 
progression is not uniform in all carriers of the mutation (Jacobson et 
al., 1997). This difference in clinical presentation among the V122I 
carriers were hypothesized in this work to be modified by the presence 
of certain non-coding genetic differences in the TTR gene similarly to 
the non-coding polymorphisms seen in an ATTRwt disease cohort. 
 The cohorts selected to be studied with the TTR-V122I mutation 
were older African American patients referred to the BU Amyloidosis 
Center Clinic between 2004 and 2019. Serum isoelectric focusing and 
subsequent TTR exon genotyping confirming the presence of the 
mutation was done on the serum samples collected from these patients 
at initial presentation. Despite most of the individuals self-identifying as 
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Black, it is important to note that genetic studies have shown that 
African Americans typically have varying levels of Caucasian gene 
admixture and thus far from a homogeneous group even within the 
different regions of the United States (Halder et al., 2012). The origin 
of the V122I mutation in the US African American population is likely to 
be from a contiguous region of West Africa based on a large study of 
genotypes from over 3000 individuals in various projects which showed 
that the V122I variant allele was most prevalent in West African 
countries including Sierra Leone, Guinea, Ivory Coast, Burkina Faso, 
Ghana, and Nigeria (Jacobson et al., 2016). The data provided in the 
study as well as haplotypes with the V122I mutation in the 1000 
Genomes Project were consistent with two ancient founder haplotypes 
carrying the V122I mutation. These observations highlight the 
complexity of the genetic heterogeneity seen in patients presenting with 
the V122I mutation. 
 The biomarkers used to define cardiac involvement in the three 
groups showed marked differences in the BNP and cTn-I between the 
non-cardiac and cardiac groups as expected with much higher than 
normal values for the cardiac groups (Table 4.2). The IVST 
measurement was not available for the cardiomyopathy non-V122I 
group but the the BNP and cTn-I levels in that group were much higher 
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than the V122I non-cardiac group. The age and sex difference observed 
(Table 4.1) between the relatively smaller group of V122I non-cardiac 
group and the other two groups were controlled for in the single marker 
and haplotype association analysis in the SNPs found between the 
groups. Despite controlling for these confounding factors, the SNP 
rs955705399 (located at position 31,590,094 in the NCBI genome build 
GRCh38.p12) showed significant difference between the V122I cardiac 
and V122I non-cardiac groups with a p-value of 0.0083 (Figure 4.7). 
At this position of the SNP, the V122I cardiac group had 51 occurrences 
of the wild-type G allele compared to 2 occurrences of the variant A 
allele whereas in the V122I non-cardiac group, there were 12 
occurrences of the wild-type G allele and 4 occurrences of the variant A 
allele. The difference in ratio of the WT allele to the variant allele in the 
two groups were very different suggesting that the presence of the 
variant A allele may benefit individuals who have not developed cardiac 
symptoms despite carrying the V122I mutation. However, it is important 
to note that the numbers of individuals in the groups studied, in 
particular the V122I non-cardiac group, were small and further studies 
of a larger population size could increase the confidence of the 
association seen in this work. Between the two cardiac groups with and 
without the V122I mutation, the SNP rs72922940 showed significance 
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with the WT A allele having 56 occurrences and the variant G allele 
having 0 occurrences in the V122I cardiac group whereas the WT A allele 
had 41 occurrences and the variant G allele had 3 occurrences in the 
cardiomyopathy non-V122I group (Figure 4.5). None of the haplotypes 
studied showed a significant association. The p-value of the single 
marker rs72922940 association was 0.0473.  
 
5.2.2 Dinucleotide region and Taq polymerase errors 
A potential issue and confounder that is important to address is 
that the Taq polymerase used in the PCR reactions to amplify the 
promoter sequence to be sequenced is prone to make errors during the 
amplification. ThermoFisher’s PCR fidelity calculator shows that the Taq 
DNA polymerase has a fidelity value of 2.28 x10-5 meaning that in the 
amplification of a 2,000 bp PCR product over 40 cycles, there is a very 
high chance of the PCR products containing artificial errors. This would 
potentially be detected as polymorphisms in the subsequent sequencing 
process and thus be indistinguishable from real polymorphisms in the 
genome. However, the 8 SNPs identified to have different alleles in the 
cohorts studied seemed to be well-documented SNPs with the observed 
minor allele frequencies matching very well with the reported minor 
allele frequencies in the African American population from the 1000 
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Genomes Project. In addition, there were no novel SNPs identified in the 
region studied confirming that the SNPs were true polymorphisms in the 
patient samples. 
 Another issue with the Sanger sequencing that was encountered 
in the study of the non-coding genetic region of the TTR gene in the 
cohort studied was an interesting region with multiple dinucleotide 
repeats with the following sequence: 
(AC)nATGCGCGT(GC)n(AC)nAT(AC)3 (Table 4.3). Regions containing 
tandem repeating DNA sequences of 1-6 base pair units have been 
shown to be interspersed throughout the eukaryotic genome (Hamada, 
Petrino, & Kakunaga, 1982; Miesfeld, Krystal, & Arnheim, 1981). There 
has been evidence of region rich in dinucleotide repeats to have a 
propensity to form an alternative form of DNA that then may have an 
effect on transcription which made this region an interesting segment to 
study (Vorlícková & Kypr, 1985; Wang, G. & Vasquez, 2007). At first 
glance sequencing through this region, the chromatogram seemed to 
contain a lot of background signal with poor quality from the sequencing 
reaction (Figure 4.8). Upon closer inspection, it seemed that the 
background signal followed the same pattern of sequences as the “main” 
sequence but with an insertion or deletion of dinucleotide repeats 
meaning that the two strands of the DNA seemed to have differing 
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numbers of dinucleotide repeats and could be parsed out manually. To 
verify that the reading through this region was indeed due to different 
dinucleotide repeats and not because of technical problems with either 
the PCR or sequencing techniques, more forward primers were designed 
closer to the region of interest. In a select few samples in which the 
sequencing from the forward direction was performed, however, the 
chromatogram did not completely match up with the reading from the 
reverse sequencing primer. This raised the possibility that the DNA 
polymerase in the sequencing reaction may not be able to read through 
this region without slippage or other errors due to the high content of 
dinucleotide repeat. It has been shown previously that the Taq DNA 
polymerase can produce stutter products when reading through 
microsatellite regions containing repeating DNA sequences (Shinde, Lai, 
Sun, & Arnheim, 2003). Alternative methods to sequence through this 
interesting region would be useful in determining the number of repeats 
in the strand with the V122I mutation and whether this region may have 
a role in the transcriptional regulation of the mutant protein. 
 
5.2.3 Serum TTR levels and comparison of wild-type and mutant TTR 




The transcriptional regulation of the TTR gene that is affected by 
the non-coding genetic changes studied in this work is postulated to lead 
to differences in serum protein level that in turn may contribute to 
disease onset. As such, in the V122I cardiac, V122I non-cardiac, and 
cardiomyopathy non-V122I groups, the serum TTR levels at initial 
evaluation at the Boston University Amyloidosis Center Clinic was 
measured. The level of TTR in the V122I cardiac group was significantly 
lower than in both the V122I non-cardiac and cardiomyopathy non-
V122I groups (Figure 4.1). This observation is consistent with the 
notion that ongoing amyloid deposition leads to lower serum TTR levels. 
Whether the deposition of circulating TTR is solely responsible for the 
lower levels is not clear. In fact, there are many factors that influence 
the circulating level of TTR including diet, many drugs such as 
corticosteroids, nutritional status, and inflammatory state, among 
others (Myron Johnson, Merlini, Sheldon, & Ichihara, 2007). It could also 
be possible that subtle effect of transcriptional downregulation of the 
TTR gene may be contributing to this lower effect due to presence of 
certain non-coding genetic changes. In particular, the difference seen 
with the SNP rs955705399 between the V122I cardiac and V122I non-
cardiac groups might be a contributory factor in disease development 
109 
 
and lower TTR levels although much more needs to be done to explore 
this potential effect. 
 In addition to measuring the serum TTR levels at initial 
presentation, the different forms of the TTR protein as measured 
through serum isoelectric focusing was quantified to better understand 
how the wild-type and mutant TTR proteins were distributed. Isoelectric 
focusing is a method that allows for sensitive measurement of the 
abundance of wild-type and variant TTR protein in the serum (Altland, 
Winter, & Sauerborn, 1999). It was found that mutant protein levels are 
consistently lower than the wild-type protein (Figure 4.2). This reflects 
that there are mechanisms in place that lead to lower circulating levels 
of the mutant protein compared to the wild-type. Whether the level of 
lower mutant protein is due to less expression compared to the wild-
type protein in the hepatocyte, altered secretion of the mutant protein, 
or higher level of clearance from serum or active deposition into target 
tissue is a very interesting question. In addition, it is also important to 
consider the possibility that chaperone activity that decreases with age 
might be a contributory factor (Soti & Csermely, 2003). While the 
numbers of individuals with either the stabilizing or non-pathologic 
mutations (H90N) were much too few to draw confident conclusions, it 
is interesting to note that 2 of the individuals with the E42G/H90N 
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compound mutations had higher mutant-WT protein ratios. This data 
suggests that there is some process (or processes) behind the higher 
level of WT protein in the serum of ATTRv patients. It will be important 
to explore this observation further to determine what exactly contributes 
to the higher level of WT protein and whether this still holds true when 
analyzing more patients with either a stabilizing or non-pathologic 
mutation.  
 
5.3 Summary and significance 
 The work detailed in this dissertation explored the effects of non-
coding genetic variations in both ATTRwt-associated disease and the 
amyloidogenic TTR-V122I mutation. In chapter 3, I studied two 
polymorphisms, rs3764479 and rs72922940, on the transcriptional 
regulation of the transthyretin gene. Previous data in an ATTRwt cohort 
found an association of rs3764479 with later age of onset of disease. I 
hypothesized that the later age of onset of disease seen with rs3764479 
was due to suppression of TTR gene transcription mediated by disruption 
of transcription factor bindings controlling TTR gene expression. This 
leads to lower TTR protein levels in the serum and as a result, slower 
deposition of the TTR protein into the cardiac tissue over the lifetime of 
an individual. I found that the SNP rs3764479 was predicted to disrupt 
111 
 
the binding of several transcription factors previously shown to regulate 
the expression of the murine TTR gene. My work showed that there were 
nuclear proteins in the hepatocellular carcinoma cell line HepG2 that 
recognized and bound to the DNA sequence where the rs3764479 is 
located. Competition assays with nucleotide probes containing 
consensus sequence for the HNF1, HNF3b, ONECUT3, and JUN showed 
evidence that these transcription factors form a protein complex that 
recognizes the sequence where rs3764479 is located. Fold excess 
competitions of the HNF1 and HNF3b consensus probes with either the 
WT- or rs3764479-containing probe-protein complex suggested that the 
HNF1 protein shows preferential binding to the sequence with 
rs3764479 variant allele and the HNF3b protein shows preferential 
binding to the sequence with the WT allele. However, the identification 
of HNF1 and HNF3b with supershift assays were not successful. 
 The effects of the rs72922940 SNP, which was most closely 
associated with disease in the ATTRwt cohort and predicted to disrupt 
the binding of C/EBPα, C/EBPβ, and HNF1, were studied with a dual-
luciferase cotransfection reporter assay. The results showed that the 
transcription factors C/EBPα and C/EBPβ had a strong repressor effect 
while HNF1 had no effect on the transcription of the TTR gene, 
regardless of the presence of rs72922940. Taken together, my work 
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suggests that the SNP rs3764479 seems to affect the binding of the 
transcription factors HNF1 and HNF3b whereas the presence of the 
rs72922940 had no effect on the transcriptional regulation of the TTR 
gene by the transcription factors C/EBPα, C/EBPβ, and HNF1. 
 In chapter 4, I studied whether the presence of non-coding 
genetic variations in the upstream regulatory region of the TTR gene are 
associated with disease in individuals with the amyloidogenic TTR-V122I 
mutation. The SNP rs955705399 was found to be significantly 
associated with development of cardiac disease in individuals with the 
V122I mutation. I posit that this mutation may also be exerting its effect 
through binding factor disruption similar to rs3764479. In measuring 
the serum TTR levels, it was found that the V122I cardiac group had 
significantly lower levels compared to the V122I non-cardiac and 
cardiomyopathy non-V122I groups. In addition, the serum levels of 
different TTR variants were found to be lower than the level of the WT 
TTR protein. I believe that this may potentially be due to transcriptional 
repression from the allele with the coding mutation in addition to the 
lower level of serum TTR reflecting an active deposition process. In such 
a way, the transcriptional dysregulation of the TTR gene could be an 
important modifier of the TTR-associated amyloidosis disease 
pathobiology and may, in part, explain the clinical heterogeneity seen 
113 
 
in patients with the same coding mutation (such as in patients with the 
V122I TTR mutation) or without a coding mutation (as in patients with 
ATTRwt disease). 
 
5.4 Future directions 
 
5.4.1 Transcription factor identification 
Although there is evidence of involvement of transcription factors 
HNF1 and HNF3b in the binding region where the rs3764479 SNP is 
located, attempts to directly identify these transcription factors in the 
protein-probe complex band were unsuccessful. The supershift assays 
would be one direct way of detection of these proteins in the protein-
probe complex in the presence of the sequence containing the WT or 
rs3764479 SNP but the antibodies I used to detect these proteins did 
not show a supershift. As discussed, this could be due to the antibodies 
not being able to recognize an epitope of the HNF1 or HNF3b that is 
accessible in the protein-probe complex. To address this issue, an 
alternative way to try to detect the transcription factors would be to use 
other antibodies that recognize different epitopes. An observation of a 
supershift in the presence of a specific antibody to those proteins would 
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be very strong evidence that these transcription factors are involved in 
the binding at the site of where the rs3764479 SNP is.  
Another approach to assess the transcription factors binding to 
the rs3764479 SNP would entail a DNA pulldown assay and mass 
spectrometry identification of the proteins. The DNA pulldown assay 
could be done with the same DNA probes that either contain the WT or 
rs3764479 sequence using a source of nuclear proteins such as the 
HepG2 nuclear extract. The protein-probe complex could be isolated 
with the help of streptavidin-conjugated magnetic beads to eliminate 
unbound proteins and permit digestion of the purified protein-probe 
complex nuclear factor identification through mass spectrometry 
analysis. Although this approach would be very time and effort-
intensive, it has the potential to identify the proteins binding to the 
region surrounding the rs3764479 SNP. This approach could also be 
modified to study different SNPs such as the rs72922940 SNP.  Moreover 
a longer probe sequence could be employed to include more flanking 
sequence if the transcription factor complex is suspected to be binding 
to a region larger than the 44-bp probe that was used to study the 
interaction. However, the downside to including more flanking sequence 




5.4.2 Expansion of TTR-V122I genetic study 
 Although the SNP rs955705399 was significantly associated with 
cardiac disease in the analysis of the V122I cardiac and V122I non-
cardiac groups, the study was limited by the group sizes. Increasing the 
group number in all three groups, including the cardiomyopathy non-
V122I group, would strengthen the findings and provide statistical 
power to potentially find new associations. Increasing the size of the 
groups could also lead to analysis of rare variants not present in the 
study cohort. With much larger group sizes, it would be interesting to 
expand the scope of the region to include the enhancer region, as it is 
involved in various transcription factor binding proven important to the 
expression of the TTR gene. 
 In addition to studying the SNPs and haplotypes, the finding of an 
interesting dinucleotide repeat region deserves further investigation. In 
order to assess disease association, correct and reliable sequencing of 
the two DNA strands would need to be done. Typical Sanger sequencing 
through this region resulted in chromatograms with a high degree of 
background signal through this region from both the forward and 
reverse direction that is likely due to the DNA polymerase not being able 
to read through a region with such repeats. An approach to address this 
issue would be to perform the PCR and sequencing reactions with high-
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fidelity PCR that would promote better stability and reading through this 
highly repeating region. 
Another aspect of the transcriptional regulation studies performed 
in Chapter 4 that is important to address is whether the SNPs studied 
are cis- or trans-regulatory to the V122I mutation. While cis-regulatory 
effects are more likely to have a direct effect on the regulation of the 
variant protein expression, trans-acting regulatory elements have also 
been described. It will be important to delineate whether the 
transcriptional control of the TTR gene affected by the presence of 
disease- and clinical feature-associated SNPs is a cis- or trans-acting 
regulatory control. 
 
5.4.3 In vivo expression in cell-based models of ATTR disease 
 The study of the non-coding genetic variations in this dissertation 
focused on transcription factor studies in vitro and in silico. To better 
understand whether these changes in the transcriptional regulatory sites 
of the TTR gene has a significant impact on the protein expression 
and/or secretion, it would be valuable to study these processes in a cell-
based model of ATTR disease. The George Murphy lab at the Center for 
Regenerative Medicine at Boston University has developed a method of 
using patient-derived induced pluripotent stem cells (iPSC) to derive 
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functional hepatocyte-like cells that can produce and secrete the 
transthyretin protein (Giadone et al., 2018). In such a cell model in 
which the genetic background of the patient is preserved, the regulation 
of the TTR gene, as well as the expression and secretion of transthyretin 
with and without particular SNPs, can provide valuable insight into 
regulation of the TTR gene. A simple experiment to study the effect of 
a single SNP could be to use two different cell lines with and without the 
SNP in the same genetic background, and then measure the mRNA and 
secreted protein levels in the hepatocyte-like cells. In this way, only the 
effect of the SNP being studied would be affecting the expression of the 
TTR gene. However, this approach is not without its downsides. The 
specification of an induced pluripotent stem cell into a hepatocyte-like 
cell is a process that can show variability in the timing of cell 
differentiation. In addition, the success of the specification process relies 
on measurement of proteins that are normally expressed by hepatocytes 
and TTR is one of the maturation markers of the hepatocyte-like cells 
(Wilson et al., 2015). However, these downsides can be minimized and 
accounted for with proper experimental design such as measuring the 
levels of different hepatic differentiation markers and thus, this 
approach can be a very useful tool to understand the functional 
significance of non-coding genetic variations in the TTR gene on gene 
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expression and protein levels. While TTR stability has been 
demonstrated to be an important contributor to disease development, it 
is very likely that there are other disease modifiers important in the 
clinical heterogeneity seen in patients with TTR-associated amyloidoses. 
The presence of non-coding variations of the TTR gene promoter that 
are significantly associated with disease and clinical features of disease 
is an interesting avenue of exploration as the regulation of the TTR gene 
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